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In a recent study, a large proportion of multi-drug-resistant (MDR) Acinetobacter baumannii strains
thatwere isolated fromhospitalized patients in theCzechRepublicwas found to belong to twomajor
groups (A and B). These groups appeared to be similar to epidemic clones I and II, respectively,
which were identified previously among outbreak strains from north-western European hospitals.
The aim of the present study was to assess in detail the genetic relatedness of Czech A. baumannii
strains and those of epidemic clones I and II by using ribotyping withHindIII andHincII and by AFLP
fingerprinting. The study collection included 70 MDR strains that were isolated in 30 Czech
hospitals in 1991–2001, 15 susceptibleCzech strains from1991 to 1996 and13 reference strains
of clones I and II from 1982 to 1990. One majorHindIII/HincIII ribotype (R1-1) was observed in 38
MDR Czech strains and eight reference strains of clone I, whereas another major ribotype (R2-2)
was observed in 11 MDR Czech strains and in three reference strains of clone II. A selection of 59
Czech strains (representative of all ribotypes) and the 13 reference strains were investigated by
AFLP fingerprinting. At a clustering level of 83%, two large clusters could bedistinguished: cluster 1
included all reference strains of clone I and 25 MDR Czech strains, whilst cluster 2 contained all
reference strains of clone II and 11 MDR Czech strains. There was a clear correlation between the
groupings by AFLP analysis and by ribotyping, as all strains with ribotype R1-1 and four strains with
slightly different ribotypes were found in AFLP cluster 1, whereas all strains with ribotype R2-2 and
seven strains with similar ribotypes were in AFLP cluster 2. Thus, 41 and 21 MDR Czech strains
could be classified as belonging to clones I and II, respectively. The remaining eight MDR and 15
susceptible strains were highly heterogeneous and were distinct from clones I and II by both AFLP
fingerprinting and ribotyping. These results indicate that the two predominant groups observed
among MDR Czech A. baumannii strains from the 1990s are genetically congruent with the north-
western European epidemic clones that were found in the 1980s. Recognition of these clinically
relevant, widespread clones is important in infection prevention and control; they are also interesting
subjects to study genetic mechanisms that give rise to their antibiotic resistance and epidemic
behaviour.
INTRODUCTION
In an extensive review, Henriksen (1973) described acineto-
bacters as soil andwater bacteria of widespread occurrence in
the surroundings of man and animals, which have low
pathogenic potential, but are opportunistic and capable of
causing infection in individuals with reduced resistance. At
the time, the genusAcinetobacter comprised only one species,
Acinetobacter calcoaceticus (Lautrop, 1974). Today, acineto-
bacters are recognized as important nosocomial pathogens
(Bergogne-Bérézin & Towner, 1996), but it is not yet well
understood to what extent this is caused by increased
susceptibility of the host or by expansion of specific strains.
Over the past three decades, considerable progress has been
made in resolving the taxonomy of the genus Acinetobacter
and in the development of methods to identify species and
strains. With the inclusion of 10 recently described species,
the genus now comprises 32 genomic species, 17 of which
have validly published names (Nemec et al., 2001, 2003; Carr
Abbreviation: MDR, multi-drug-resistant.
A table showing data on origin and properties of the strains used in this
study is available in JMM Online.
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et al., 2003). A few are of undisputed clinical relevance,
whereas many others may be true environmental organisms,
although the ecology of most species is as yet unrevealed.
Among the clinically relevant species,Acinetobacter bauman-
nii is the most common in clinical specimens and can give
rise to severe infections in critically ill patients. Strains of this
species that circulate on intensive-care units are frequently
multi-drug-resistant (MDR) and combine this feature with
the capacity to spread among patients and to persist in the
hospital environment (e.g. Aygun et al., 2002; Wang et al.,
2003).
In the mid 1990s, A. baumannii strains from 14 outbreaks
and 17 sporadic strains from hospitals in different north-
western European cities and countries were compared to
assess the diversity among outbreak and non-outbreak
strains. By using a combination of genotypic and phenotypic
methods, the outbreak strains could be allocated to twomain
groups (designated clones I and II), whereas the sporadic
strainsweremore heterogeneous (Dijkshoorn et al., 1996). In
a more recent study, phenotypic and genotypic properties of
A. baumannii hospital strains from the Czech Republic were
studied (Nemec et al., 1999). It was found that MDR strains
showed lower variability than susceptible strains.MostMDR
strains were classified into two groups (designated A and B),
each of which was characterized by a specific ribotype and
similarity in other properties. The grouping of two reference
strains of clones I and II with strains of groups A and B,
respectively (Nemec et al., 1999), and apparent similarities in
ribotypes of strains of clones I and II with groups A and B,
respectively (Pantophlet et al., 2001), suggested that the
respective clones and groups were congruent. Similarity of
strains of group A and clone I was corroborated by their
common reactivity with O-antigen-specific mAbs (Panto-
phlet et al., 2001).
The panels of methods that were used to delineate clones I
and II and groups A and B were different; therefore, definite
conclusions on their genetic relatedness cannot bemade until
a representative sample of strains is subjected to common
methods. The aimof the present studywas to analyse in detail
genotypic similarities between A. baumannii hospital strains
from the Czech Republic and those that are representative of
north-western European clones, in order to assess whether
there is a pan-European presence of particular, genetically
highly related, MDR strains (i.e. clones). For this purpose,
the collection of Czech strains that was used in the previous
study was enlarged with recent Czech MDR isolates. Strains
were studied by ribotyping and by high-resolution AFLP
fingerprinting, which has been found to be useful for the
differentiation of Acinetobacter strains at the subspecies level
(Dijkshoorn et al., 1996; Janssen & Dijkshoorn, 1996; van
Dessel et al., 2003).
METHODS
Bacteria. Two sets of Czech A. baumannii strains were used in this
study. Set ARC included 52 archive strains that were isolated in the
Czech Republic between 1991 and 1999. These strains were selected
frommore than 700 clinical Acinetobacter isolates, in order to comprise
hospital strains that were as heterogeneous as possible in terms of their
time of isolation and geographical origin (18 cities were included). The
ARC strains had been characterized in detail previously and were
classified into groupA (n 23), groupB (n 7), a group of otherMDR
strains (n 7) and a group of susceptible strains (n 15) (Nemec et al.,
1999; Pantophlet et al., 2001).
Set REC comprised 33 recent MDR A. baumannii strains from Czech
hospitals that were selected, according to biochemical characteristics
and susceptibility to antibiotics, from 250 clinical isolates that were
referred to the National Institute of Public Health in 2000 and 2001.
Strains were selected to be as geographically heterogeneous as possible
(from 20 hospitals in 13 cities). Multiple isolates from the same hospital
were not considered to be epidemiologically related, as assessed by
biotyping (Bouvet & Grimont, 1987) and/or macrorestriction analysis
of genomic DNA (Nemec, 1999). REC strains were recovered from
sputum (n 9), urine (n 7), blood (n 7), wound swabs (n 4)
and other clinical specimens, most of which were taken from intensive-
care unit patients.
Reference strains of epidemic clones were RUH 436, RUH 510, RUH
875, RUH 2037, RUH 3238 ( GNU 1084), RUH 3239 ( GNU 1083),
RUH 3242 ( GNU 1082), RUH 3247 ( GNU 1078) and RUH 3282
( GNU 1079) for clone I, and RUH 134, RUH 3240 ( GNU 1086),
RUH 3422 ( PGS 189) and RUH 3245 ( GNU 1080) for clone II.
These strains were characterized in detail previously (Dijkshoorn et al.,
1996; Pantophlet et al., 2001).
Phenotypic characteristics of all strains corresponded to those of the
genus Acinetobacter (Juni, 1984). Strains were identified as A. bauman-
nii according to EcoRI ribotypes (Nemec et al., 1999) and were allocated
to the biotypes of Bouvet &Grimont (1987) on the basis of utilization of
laevulinate, citraconate, L-phenylalanine, phenylacetate, 4-hydroxy-
benzoate and L-tartrate.
Ribotyping. Ribotyping was carried out as described previously
(Nemec et al., 1999), with minor modifications. Total DNA was
prepared by using SDS lysis, proteinase K treatment and phenol/
chloroform extraction. Digestion was performed with HindIII and
HincII in two separate steps. These enzymeswere selected for the present
study because they were found to show an optimal distribution of
fragments for pattern analysis, compared to 15 enzymes tested [includ-
ing EcoRI, which was used in previous studies (Nemec et al., 1999;
Pantophlet et al., 2001)]. Electrophoretic separation of DNA fragments
was done in 0.7% (HindIII) or 0.8% (HincII) agarose in TBE buffer
(45 mM Tris/borate, 1 mM EDTA, pH 8.0) for 16 h. The voltage used
was 45 and 35 V for HindIII and HincII, respectively. Fragments were
blotted onto a nylonmembrane, hybridized with a digoxigenin-labelled
16S–23S probe and visualized immunochemically. The resulting
patterns were compared visually and distinct ribotypes were numbered
arbitrarily. Each strain was characterized by a combinedHindIII/HincII
ribotype, e.g. R1-1. For cluster analysis, the presence or absence of a
band at each position was scored as plus or minus, respectively.
Percentage disagreement was used as ameasure of dissimilarity between
all pairs of HindIII/HincII ribotypes; it was expressed as the percentage
of band position differences in a pair of ribotypes out of the total
number of band positions (found in all ribotypes). Grouping was
obtained by the UPGMA algorithm. All calculations were performed by
using Statistica 5.1 software (StatSoft).
AFLP. AFLP fingerprinting was performed according to Nemec et al.
(2001). Briefly, purified DNA was digested by using EcoRI and MseI,
while ligation of EcoRI and MseI adaptors was performed simulta-
neously. PCR was done with a Cy5-labelled EcoRI + A primer and a
MseI + C primer (A and C represent selective nucleotides). The
ALFexpress II DNA analysis system (Amersham Biosciences) was used
for fragment separation. Fragments of 50–500 bp were subjected to
16
cluster analysis by using the BioNumerics software package, release 2.5
(Applied Maths), with an overall tolerance setting of 0.11%. The
Pearson product–moment coefficient (r) was used as the measure of
similarity and UPGMA was used for grouping.
Antibiotic susceptibility testing. Antimicrobial susceptibility was
determined by the disc diffusion method on Mueller–Hinton agar
(Oxoid). Antimicrobial agents tested (Oxoid) were ( g per disc):
ampicillin + sulbactam (10 + 10), piperacillin (100), ceftazidime (30),
imipenem (10), gentamicin (10), tobramycin (10), amikacin (30),
netilmicin (30), ofloxacin (5), cotrimoxazole (sulphamethoxazole +
trimethoprim: 23.75 + 1.25) and tetracycline (30). Interpretative cut-
off values for resistance were adjusted according to the known
distribution of inhibition zone diameters among A. baumannii strains
(Nemec, 1999). These values were identical to those recommended by
the National Committee for Clinical Laboratory Standards (NCCLS,
2001) for intermediate categories except for tetracycline and piper-
acillin, for which the NCCLS values for resistance were used. Multi-
resistance was defined as resistance to at least two antibiotics that
represent different antibiotic classes.
RESULTS AND DISCUSSION
Ribotyping
Ribotyping of all 98 strains with HindIII and HincII
separately revealed 33 and 25 different band positions,
respectively. In total, 24 different HindIII ribotypes, 20
HincII ribotypes and 29 combinations ofHindIII andHincII
ribotypes were identified. Examples of HindIII and HincII
ribotypes are shown in Fig. 1. Themost frequent ribotypewas
R1-1, which was found in 38MDRCzech strains and in eight
reference strains of clone I. Czech strains with ribotype R1-1
had previously been classified as group A. The second most
frequent ribotype was R2-2, which was found in 11 MDR
Czech strains and three reference strains of clone II. Czech
strains with this ribotype had previously been classified as
group B. Strain RUH 3242 (clone I) was of ribotype R3-1,
whereas RUH 3240 (clone II) was of ribotype R4-2. These
ribotypes were also found inMDR Czech strains. Each of the
susceptible strains showed a uniqueHindIII/HincII ribotype.
AFLP
A selection of 72 strains, which included 59Czech strains that
were representative of all different ribotypes and the 13
reference strains of clones I and II, was studied by AFLP.
Frequent ribotypes were represented by several strains, which
differed mostly in other characteristics (biotype, plasmid
profile and antibiotic susceptibility). Clustering of the strains
according to their AFLP fingerprints is shown in Fig. 2. At a
level of 83%, two major clusters of MDR strains could be
distinguished: cluster 1 included all strains with ribotypes
R1-1 and R3-1 and one strain with the unique ribotype R5-3;
whereas cluster 2 included strains with ribotype R2-2 and
four other ribotypes (R2-4, R4-2, R2-5 and R6-4). AFLP
patterns of all susceptible strains and otherMDR strains were
heterogeneous and clearly distinct from those of strains
included in clusters 1 and 2.
Correlation between ribotyping and AFLP
There was a good correlation between AFLP and ribotyping
results. Both AFLP clusters 1 and 2 contained strains of either
identical or similar ribotypes that were specific for each of the



















































Fig. 1. Examples of (a) HindIII and (b) HincII ribotypes observed for A.
baumannii strains. Strains are indicated by upper-case letters above
the lanes: A, NIPH 7; B, NIPH 1605; C, NIPH 10; D, NIPH 24; E, NIPH
1362; F, NIPH 657; G, NIPH 301; H, NIPH 601. M, Molecular size
marker (º-phage DNA digested with HindIII and StyI). Ribotype
designations are given below the lanes.
A. baumannii
clusters. This correlation was also found for strains linked in
other clusters above 83%, i.e. NIPH 1497 and NIPH 1683 or
NIPH 335 and NIPH 1445 (Fig. 2). Clustering of HindIII/
HincII ribotypes is shown in Fig. 3. Ribotypes R1-1 and R2-2,
which predominated among strains of AFLP clusters 1 and 2,
respectively, were clearly distinct from each other (15 band
differences in total). Differences between non-identical
ribotypes of strains of the same AFLP cluster were small
(Fig. 3). However, high similarity of some ribotypes was not
confirmed by AFLP, e.g. strain NIPH 410, with a ribotype
highly similar to R1-1 (one band difference), was clearly
different from clone I strains according to its AFLP pattern
(Fig. 2) and other properties (Nemec et al., 1999). This shows
the limitation of ribotyping in estimating genetic relatedness
of strains.
Relationship between theCzech groups and clones
I and II
So-called epidemic clones I and II were distinguished
originally among outbreak A. baumannii strains from
north-western European hospitals on the basis of similarities
in their genotypic and phenotypic properties (Dijkshoorn
et al., 1996). Within these clones, there was some intraclonal
variability, but AFLP fingerprinting allowed unambiguous
allocation of all strains to either clone I or clone II at a
clustering level of 90%. A further study showed that most
MDR Czech strains belonged to two main groups, A and B,
the delineation of which was based on identity in EcoRI
ribotypes and supported by similarities in biochemical
properties and plasmid profiles. It also appeared that groups
A and B were similar to clones I and II, respectively, based on
visual comparison of EcoRI ribotypes in studies that deli-
neated these groups and clones, on inclusion of two reference
strains of clones I and II in the study onCzech strains (Nemec
et al., 1999) and on common reactivity of clone I and groupA
strains with O-antigen-specific mAbs (Pantophlet et al.,
2001). However, as intraclonal variability of EcoRI ribotypes
Fig. 2. Cluster analysis of AFLP fingerprints of 59 Czech A. bauman-
nii strains (representative of different ribotypes) and 13 reference
strains (RUH) for clones I and II. Strains NIPH 4–NIPH 657 belong to
set ARC and strains NIPH 1362–NIPH 1729 belong to set REC.
Susceptible strains are underlined. RT, HindIII-HincII ribotypes; BT,
biotypes according to Bouvet & Grimont (1987); mAb, reactivity with
O-antigen-specific mAbs (Pantophlet et al., 2001). NG, No growth on
mineral medium; NR, no reactivity with any of 20 antibodies tested; NT,
not tested; NW, novel biotype.
Fig. 3. Cluster analysis of HindIII/HincII ribotypes found in 85 Czech
A. baumannii strains. No. strains with a respective ribotype is indicated
in parentheses. Grouping was obtained by the UPGMA algorithm by
using percentage disagreement. d, Ribotypes of strains of AFLP
cluster I (clone I); h, ribotypes of strains of AFLP cluster II (clone II).
was found in clone II (Dijkshoorn et al., 1996) and could not
be excluded for clone I, the relationship between the clones
and some Czech strains remained unclear.
In the present study, a combination of ribotyping and AFLP
results allowed the classification of 62 of 70 (89%) MDR
Czech strains into the north-western European clones. The
current AFLP protocol was different from that used pre-
viously (Dijkshoorn et al., 1996) with respect to the choice of
restriction enzymes and selective primers and method of
fragment separation. By this modified procedure, reference
strains of clones I and II were linked at a level of 83% in two
major clusters. In total, 36 of 44 MDR Czech strains,
including the strains allocated previously to groups A and
B and strains with ribotypes that were highly similar to those
of groups A and B, were found in these respective clusters.
According to the positions and interrelatedness of strains in
AFLP clusters 1 and 2 and overall similarity of their ribotypes
and other characters (biotype, serotype defined by O-anti-
gen-specific mAbs and plasmid content), we conclude that
the Czech strains in these clusters belong to the previously
described clones I and II (Fig. 2, Table 1). Similarity of AFLP
and ribotypes are useful criteria to identify strains that belong
to these clones.
Eight MDR and 15 susceptible strains were clearly distinct
genotypically from clones I and II. These strains were highly
heterogeneous in their AFLP pattern, ribotype (21 HindIII/
HincII ribotypes), biotype (10 different biotypes), serotype
(Pantophlet et al., 2001) and plasmid profile (Nemec et al.,
1999). Similarly, remarkable heterogeneity of phenotypic
and genotypic features was found among the strains from
north-western Europe that were not allocated to clone I or II
(Dijkshoorn et al., 1996). These findings are suggestive of
high genetic diversity in the general A. baumannii popu-
lation.
Multi-drug resistance in Czech strains
Resistance of the Czech strains to 11 antibiotics is shown in
Table 2. It is noteworthy that there was an apparent
discontinuity in qualitative resistance between the suscep-
tible and MDR strains, as shown in our previous study
(Nemec et al., 1999). Most susceptible strains were not
resistant to any of the antibiotics tested, whereas 90% of
MDR strains showed resistance to five or more antibiotics. If
susceptible to an antibiotic, MDR strains often had a smaller
inhibition zone than susceptible strains (see Supplementary
Table in JMM Online), which is indicative of their higher
potential for being refractory to antimicrobial therapy.
Intraclonal diversity
Table 1 summarizes the ribotyping and biotyping results of
the present study and those of biotyping, serotyping and
plasmid analysis that were obtained previously (Nemec et al.,
1999; Pantophlet et al., 2001). The data demonstrate some
intraclonal variability in ribotype, biotype and serotype.
Strains of clones I and II that were analysed in the present
study were also heterogeneous in antibiotic resistance profile
(see Supplementary Table in JMM Online) and plasmid
profile (Nemec et al., 1999). This intraclonal variation may
result from ongoing diversification in space and time. One
example of this diversification is the clone II strains that
Table 1. Properties of A. baumannii strains in clones I and II
Data are from this study, Nemec et al. (1999) and Pantophlet et al. (2001). Numbers in parentheses indicate no. strains with respective types. NT, Not















ARC 1991–1999 24 R1-1 (23), R5-3 (1) 6 (9), 11 (14) 7.1 [2–10] S48-3-13 (18);
S51-3 (6)
24
REC 2000–2001 17 R1-1 (15), R3-1 (2) 6 (6), 11 (10), 12 (1) 7.1 [5–10] NT NT
Reference strains 1984–1990 9 R1-1 (8), R3-1 (1) 6 (8), 11 (1) 6.6 [4–9] S48-3-13 (9) 9
Clone II:
ARC 1991–1997 10 R2-2 (7), R6-4 (3) 2 (10) 5.7 [3–8] S53-32 (7); NR (3) 1
REC 2000–2001 11 R2-2 (4), R6-4 (1),
R4-2 (3), R2-5 (2),
R2-4 (1)
2 (11) 5.8 [3–7] NT NT
Reference strains 1982–1989 4 R2-2 (3), R4-2 (1) 1 (1), 2 (2), 9 (1) 3.8 [1–5] S48-3-17 (3); NR (1) 1
*Biotype according to Bouvet & Grimont (1987). One clone I strain (set ARC) was auxotrophic.
†Eleven antibiotics were tested (see Methods). Values are means, with range in square brackets.
‡Twenty mAbs against O-antigens were tested (Pantophlet et al., 2001).
A. baumannii
shared ribotype R4-2 and grouped in a distinct AFLP
subcluster at a level of 88%. Another example, although
not reflected in the AFLP clustering pattern, is the Czech
clone I strains of biotype 11. This biotype was the most
frequent in Czech A. baumannii strains (Nemec et al., 1999),
but seems relatively rare in western Europe (Bouvet &
Grimont, 1987; Seifert et al., 1993). Most Czech strains of
biotype 11 showed similarity in other properties (ApaI
macrorestriction analysis profiles, inability to grow on L-
arabinose and the presence of a 6 kb plasmid; data not
shown) and are likely to represent a regional subclone. Thus,
despite the noted similarity of strains that belong to the same
clone, there are still characters that can be used to identify
strains for epidemiological purposes.
Geographical spread of the clones
Our results and data from the literature indicate a pan-
European spread of strains that are classifiable in clones I or II
over a remarkable period of time. These strains were spread
widely in Czech hospitals from at least 1991 to 2001 and were
found in the Netherlands, the UK, Belgium and Denmark
between 1982 and 1990 (Dijkshoorn et al., 1996). They were
also recognized by Brisse et al. (2000) and van Dessel et al.
(2003) among quinolone-resistant A. baumannii isolates
from different parts of Europe, including southern Europe,
and one isolate from South Africa. Visual inspection of EcoRI
ribotypes that were published by Seifert & Gerner-Smidt
(1995) also suggests the occurrence of these strains in Danish
and German hospitals. Finally, Pantophlet et al. (2001, 2002)
have shown that serotypes found in strains of clones I and II
(Table 1) are spread among A. baumannii strains from
European countries, including Bulgaria and Hungary.
In conclusion, the results presented here confirm that MDR
Czech strains of A. baumannii that were isolated from
hospitalized patients belong mainly to two genetically dis-
tinct groups that were identified originally among strains in
north-western Europe. These groups most probably repre-
sent old clones in a broad (evolutionary) sense, as can be
judged from the noted intraclonal type variation and their
wide distribution in space and time, as opposed to recent
clonal lineages that are found in local outbreaks, which are
usually relatively uniform in type characters. It is not yet
known what properties have facilitated the wide spread of
these MDR clones. It is possible that the capacity to develop
or acquire antibiotic resistance was already an attribute of
their ancestors and is a prerequisite for their success. There-
fore, these clones, which are of undisputed clinical signifi-
cance, are challenging targets for research on the evolution
and spread ofmulti-drug resistance andof factors involved in
A. baumannii epidemicity and pathogenicity.
Deposition of representative Czech strains in the
CCM
The following strains were deposited in the Czech Collection
of Microorganisms (CCM): CCM 7031 ( NIPH 7; clone I,
the reference strain of group A), CCM 7032 ( NIPH 15;
clone I/groupA), CCM7034 ( NIPH281; clone I/groupA),
CCM 7116 ( NIPH 10; clone I), CCM 7033 ( NIPH 24;
clone II, the reference strain of group B), CCM 7117
( NIPH 657; clone II) and CCM 7118 ( NIPH 1362;
clone II). The origin and properties of these strains are
available in the Supplementary Table in JMM Online.
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Ampicillin + sulbactam 61 57 25 0
Ceftazidime 41 67 13 0
Imipenem 0 10 25 0
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Tetracycline 98 100 88 7
*The majority of non-resistant strains showed reduced inhibition zone diameters (15–19 mm) in
comparison with the susceptible strains (23–26 mm).
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The purpose of the present study was to investigate the diversity of the genes encoding
aminoglycoside-modifying enzymes and their association with class 1 integrons in three pan-
European clones ofAcinetobacter baumannii. The study collection included106multidrug-resistant
strains previously allocated to clone I (n 56), clone II (n 36) and clone III (n 6) and a
heterogeneous group of other strains (n 8), using AFLP fingerprinting and ribotyping. The strains
were from hospitals of the Czech Republic (n 70; collected 1991–2001) and 12 other European
countries (n 36; 1982–1998). Using PCR, at least one of the following aminoglycoside-
resistance genes was detected in 101 (95%) strains: aphA1 (n 76), aacC1 (n 68), aadA1
(n 68), aphA6 (n 55), aadB (n 31), aacC2 (n 7) and aacA4 (n 3). A combination of two
to five different resistance genes was observed in 89 strains (84%), with a total of 12 different
combinations. PCR mapping revealed that aacC1, aadA1 and aacA4 were each associated with a
class 1 integron, as was the case with aadB for six strains of clone III. Six different class 1 integron
variable regionswere detected in 78strains (74%),with twopredominant regions (2.5 and3.0 kb) in
two sets of 34 strains each. The 3.0 kb region contained five gene cassettes (aacC1, orfX, orfX,
orfX9, aadA1) and differed from the 2.5 bp region only by one additional orfX cassette. These two
integron regionswere confined to clones I and II andwere found in strains isolated in seven countries
between 1982 and 2001. The clone III strains were homogeneous both in resistance genes and in
integron variable regions, whereas clones I and II showed a remarkable intraclonal diversity of these
properties, with no clear-cut difference between the two clones. Yet, within the Czech clone I and II
strains, the diversity of resistance genes and integron structures was limited as compared to those
from other countries. The occurrence of identical resistance genes, gene combinations and class 1
integrons associated with these genes in clonally distinct strains indicates that horizontal gene
transfer plays a major role in the dissemination of aminoglycoside resistance in A. baumannii.
INTRODUCTION
Acinetobacter baumannii is an important opportunistic
pathogen that has the potential to spread among hospitalized
patients and persist in the hospital environment (Bergogne-
Bérézin & Towner, 1996). Recent studies have identified
Abbreviation: MDR, multidrug-resistant.
The GenBank/EMBL/DDBJ accession number for the sequence of the
3.0 kb integron variable region of NIPH7 ( CCM7031 LMG22454) is
AY577724.
Information on properties and origin of the strains used in this study is
available as supplementary data in JMM Online.
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A. baumannii clones
three clones among multidrug resistant (MDR) isolates of A.
baumannii from hospitals in different European countries.
These included clones I and II from north-western Europe in
the period 1982–1990 (Dijkshoorn et al., 1996), which were
also found to prevail in the Czech Republic between 1991 and
2001 (Nemec et al., 2004), and clone III delineated among
western European and Spanish strains from 1997 to 1998
(van Dessel et al., 2004).
Aminoglycosides have long been used for the treatment of
infections in hospitalized patients and still are an important
alternative for therapy of infections caused by MDR strains.
Previous studies have shown a high diversity of mechanisms
of resistance to these antibiotics in the genus Acinetobacter
(Shaw et al., 1993; Miller et al., 1995). Resistance to
aminoglycosides has been attributed mainly to enzymic
inactivation by acetyltransferases, nucleotidyltransferases
and phosphotransferases (Shaw et al., 1993), and Acineto-
bacter strains often contain multiple enzymes of these classes
(Miller et al., 1995; Seward et al., 1998). The genes encoding
aminoglycoside-modifying enzymes can be located on plas-
mids and transposons (Devaud et al., 1982), and some of
these genes have been found on class 1 integrons in MDR A.
baumannii strains in Europe (Seward & Towner, 1999;
Gallego & Towner, 2001; Gombac et al., 2002; Ribera et al.,
2004).
Multidrug resistance is a striking feature of the strains
belonging to clones I, II and III, and usually includes
resistance to aminoglycosides. Overall, there is a great
diversity in resistance phenotypes within the clones (Nemec
et al., 2004) but the genetic basis of this diversity has not been
studied yet. Since multiple mechanisms may give rise to
similar phenotypes, it is not known whether there is an
association of particular antibiotic-resistance determinants
with specific clones. The aim of the present study was to
investigate the genetic basis of aminoglycoside resistance in
the pan-European A. baumannii clones. To this aim, the
occurrence of different genes encoding aminoglycoside-
modifying enzymes and their correlation with aminogly-
coside-resistance phenotypes was investigated in a set of
well-defined strains from the Czech Republic and other
European countries belonging to the three described clones.
In addition, the structural types of class 1 integron variable
regions and their association with aminoglycoside-resistance
genes were assessed.
METHODS
Bacteria. A total of 106 MDR clinical A. baumannii strains from
hospitals in the Czech Republic and other European countries were
studied (Table 1). The collection comprised strains classified into clones
I (n 56), II (n 36) and III (n 6), and a heterogeneous group of
other strains (n 8). The Czech strains (n 70) were isolated in 23
cities between 1991 and 2001 and were described recently (Nemec et al.,
2004). The non-Czech strains (n 36) were isolated in 25 cities from 12
European countries between 1982 and 1998 and, except for four strains
from Eastern Europe, have also been described previously (Dijkshoorn
et al., 1996; vanDessel et al., 2004). All Czech strains and 13 other strains
of clones I and II (Dijkshoorn et al., 1996) have been characterized
uniformly by AFLP, HindIII–HincII ribotyping and biotyping (Nemec
et al., 2004). For reasons of harmonization, the remaining strains, i.e. 19
of the study of van Dessel et al. (2004) and four Eastern European
strains, were analysed by this panel of methods in the present study.
Antibiotic susceptibility testing. Susceptibility was determined by
the disk diffusion method according to the National Committee for
Clinical Laboratory Standards (NCCLS) recommendations (NCCLS,
2000) using Mueller–Hinton agar (Oxoid) and the following anti-
microbial agents ( g per disk): kanamycin (30), gentamicin (10),
tobramycin (10), amikacin (30) and netilmicin (30) (Oxoid). MICs of
gentamicin, tobramycin, amikacin and netilmicin (MAST Group) were
determined by the agar dilution method according to the NCCLS
recommendations (NCCLS, 2003).
Detection of aminoglycoside-resistance genes. The presence of
genes encoding the following aminoglycoside-modifying enzymes was
investigated by PCR: phosphotransferases APH(39)-Ia (aphA1) and
APH(39)-VIa (aphA6), acetyltransferases AAC(3)-Ia (aacC1), AAC(3)-
IIa (aacC2) and AAC(69)-Ib (aacA4), and nucleotidyltransferases
ANT(299)-Ia (aadB) and ANT(399)-Ia (aadA1). The primers were those
described by Noppe-Leclercq et al. (1999) for aphA1, aacC1, aacC2,
aacA4 and aadB, byVila et al. (1999) for aphA6 and byClark et al. (1999)
for aadA1. PCR reactions were performed in a final volume of 20 l
containing 10 l Taq PCRMaster Mix (Qiagen), 0.2 M of each primer
and 1.5 l of aDNA suspension obtained by alkaline lysis as described by
Nemec et al. (2000). The amplification reactions were performed in a
FTGENE2D thermal cycler (Techne) with the following parameters:
94 8C for 2 min, followed by 30 cycles of 30 s at 94 8C, 30 s at 55 8Cand60
s at 72 8C. The presence and sizes of amplicons were assessed by
electrophoresis in 2% agarose gels stained with ethidium bromide.
Integronanalysis.The presence of class 1 integrons was determined by
PCR amplification of an internal fragment of the integrase gene (intI1)
using the primers described by Koeleman et al. (2001). Amplification
mixtures and conditionswere as specified above. To detect inserted gene
cassettes, variable regions of class 1 integrons were amplified with
primers 59CS and 39CS, which are complementary to 59 and 39
conserved segments flanking the inserted DNA (Lévesque et al.,
1995). The association of aminoglycoside genes with integrons and
the position of the associated genes inside the variable regions were
investigated using PCR mapping with primer sets comprising the 59CS
primer and a primer for each individual gene (Lévesque et al., 1995). The
amplification protocol used for the 59CS–39CS amplification and PCR
mapping consisted of 2 min at 94 8C, 35 cycles of 45 s at 94 8C, 45 s at
55 8C and 5 min at 72 8C, and a final extension of 7 min at 72 8C, while
the PCR mixtures were prepared as described above. The sequence
similarity of amplicons of the same size was investigated by restriction
analysis with HinfI and RsaI in separate reactions. The nucleotide
sequence of the cloned 3.0 kb variable region from strain NIPH 7 was
determined by the dideoxy chain-termination method using an auto-
matic DNA sequencer (ALFexpress II; Amersham Biosciences).
RESULTS AND DISCUSSION
Table 1 shows the distribution of the aminoglycoside-
resistance genes, class 1 integron structures and resistance
phenotypes of the strains arranged according to their clonal
types. A more comprehensive table including quantitative
antibiotic susceptibility data is available as supplementary
data in JMM Online.
Table 1. Properties of the 106 strains studied
The strains were allocated to clones on the basis of the grouping obtained byAFLP andHindIII–HincII ribotyping (Nemec et al., 2004) and are classified
successively according to ribotype, resistance gene content, integron type, phenotype and country of isolation. The results of ribotyping and biotyping
forNIPHandRUHstrains are fromNemec et al. (2004). Resistance phenotypes for kanamycin (K), gentamicin (G), netilmicin (N), tobramycin (T) and
amikacin (A) were determined using the disk diffusion test and NCCLS breakpoints for resistance (NCCLS, 2000). RT,HindIII–HincII ribotypes; BT,
biotypes according to Bouvet & Grimont (1987); , not found; NG, no growth on minimal medium; BE, Belgium; BG, Bulgaria; CZ, Czech Republic;
DK, Denmark; ES, Spain; FR, France; GR, Greece; HU, Hungary; IT, Italy; NL, the Netherlands; PL, Poland; PT, Portugal.









Clone I (n 56)
NIPH 188, NIPH 281,
NIPH 307, NIPH 309,
NIPH 357, NIPH 1486
1-1 aacC1, aphA1, aphA6, aadB 3.0 K, G, T, A 11 CZ (1993–2001) 1
NIPH 290 1-1 aacC1, aphA1, aphA6, aadB 3.0 K, G, N, T, A 11 CZ (1994) 1
NIPH 1477 1-1 aacC1, aphA1, aphA6, aadB 3.0 K, G, T 11 CZ (2001) 1
LUH 1396 1-1 aacC1, aphA1, aphA6, aadB 2.5 K, G, T, A 6 BG (1997)
LUH 6017 1-1 aacC1, aphA1, aphA6, aadB 2.5 K, G, T, A 6 IT (1998) 3
NIPH 1475, NIPH 1693,
NIPH 1729
1-1 aacC1, aphA1, aphA6, aadB 2.5 K, G, T, A 11 CZ (2001) 1
NIPH 409, NIPH 1150,
NIPH 1359, NIPH 1488,
NIPH 1499, NIPH 1574
1-1 aacC1, aphA1, aphA6 2.5 K, G, A 6 CZ (1996–2001) 1
NIPH 7,NIPH 321, NIPH 392,
NIPH 857, NIPH 881,
NIPH 1500
1-1 aacC1, aphA1, aphA6 3.0 K, G, A 11 CZ (1991–2001) 1
NIPH 921 1-1 aacC1, aphA1, aphA6 3.0 K, G, A NG CZ (1997) 1
NIPH 207 1-1 aacC1, aphA1, aphA6 3.0 K, G 11 CZ (1992) 1
RUH 3282 ( GNU 1079) 1-1 aacC1, aphA1, aphA6 3.0 K, G, N, A 11 UK (1990) 1, 2
NIPH 15, NIPH 360 1-1 aacC1, aphA1 3.0 K, G 6 CZ (1991–1994) 1
RUH 436, RUH 510,
RUH 2037
1-1 aacC1, aphA1 3.0 K, G 6 NL (1984–1986) 1, 2
RUH 3238 ( GNU 1084),
RUH 3239 ( GNU 1083)
1-1 aacC1, aphA1 3.0 K, G 6 UK (1985–1988) 1, 2
NIPH 1587, NIPH 1731 1-1 aacC1, aphA1 3.0 K, G 11 CZ (2001) 1
LUH 6015 1-1 aacC1, aphA1 2.5 K, G 6 IT (1998) 3
NIPH 1520, NIPH 1672 1-1 aacC1, aphA1 2.5 K, G 6 CZ (2001) 1
NIPH 408 1-1 aacC1, aphA1, aadB 3.0 K, G, T 11 CZ (1996) 1
NIPH 693 1-1 aacC1, aphA6, aadB 3.0 K, G, T, A 11 CZ (1997) 1
NIPH 878 1-1 aacC1, aphA6 2.5 K, G, A 6 CZ (1998) 1
RUH 875 1-1 aphA1, aadB 0.7 K, G, T 6 NL (1984) 1, 2
RUH 3247 ( GNU 1078) 1-1 aphA1, aacA4 0.8 K, G, N, T 6 BE (1990) 1, 2
LUH 5881 1-1 aphA1, aacA4 0.8 K, G, N, T, A 6 ES (1998) 3
NIPH 1358 1-1 aphA6, aadB K, G, T, A 12 CZ (2000) 1
NIPH 470 1-1 aphA6 K, N, A 6 CZ (1997) 1
NIPH 654 1-1 aphA6 K, A 6 CZ (1996) 1
LUH 3584 1-1 aadB K, G, T 6 HU (1995)
NIPH 56 1-1 6 CZ (1992) 1
NIPH 1605 3-1 aacC1, aphA1, aadB 2.5 K, G, T 11 CZ (2001) 1
RUH 3242 ( GNU 1082) 3-1 aacC1, aphA1 3.0 K, G 6 UK (1989) 1, 2
LUH 6125 ( 14C052) 3-1 aacC1, aphA6 3.0 K, G, A 11 PL (1998) 3
NIPH 1722 3-1 aphA6, aadB K, G, T, A 11 CZ (2001) 1
NIPH 10 5-3 aacC1, aphA1, aphA6 3.0 K, G, N, A 6 CZ (1991) 1
Clone II (n 36)
NIPH 455 2-2 aacC1, aphA1, aphA6 2.5 K, G, A 2 CZ (1996) 1
LUH 1398 2-2 aacC1, aphA1, aphA6 2.5 K, G, A 2 BG (1997)




A total of 102 strains (96%)were fully resistant to at least one
of kanamycin, gentamicin, tobramycin, netilmicin or ami-
kacin, and at least one resistance gene was detected in 101
strains (95%). The distribution of individual resistance
genes among the strains is shown in Table 2. The observed
high frequency of aphA1, aadA1, aacC1, aphA6 and aadB is in
agreement with the previously published data on clinical
isolates of Acinetobacter spp. (Shaw et al., 1993) and
A. baumannii (Seward et al., 1998). There was a good
correlation between the content of resistance genes and
Table 1. cont.









LUH 1245 2-2 aacC1, aphA1, aadB 2.5 K, G, T 2 HU (1993)
RUH 134 2-2 aacC1, aphA1 3.0 K, G 1 NL (1982) 1, 2
NIPH 24, NIPH 330, NIPH
471, NIPH 499, NIPH 1526,
NIPH 1567, NIPH 1696
2-2 aacC1, aphA1 2.5 K, G 2 CZ (1991–2001) 1
NIPH 220 2-2 aacC1, aphA1 2.5 K, G, N, T, A 2 CZ (1993) 1
NIPH 141 2-2 aacC1 2.5 G 2 CZ (1993) 1
LUH 6034 2-2 aphA6, aacC2 K, G, N, A 2 ES (1998) 3
RUH 3422 ( PGS 189) 2-2 aphA1 K 2 DK (1984) 1, 2
NIPH 1462 2-2 aphA1 K 2 CZ (2001) 1
RUH 3245 ( GNU 1080) 2-2 aacC2 G, N 9 UK (1989) 1, 2
LUH 6126 ( 15A250) 2-4 G, N 1 PT (1998) 3
NIPH 1628 2-4 2 CZ (2001) 1
NIPH 1511, NIPH 1629 2-5 aacC1, aphA1 3.0 K, G 2 CZ (2001) 1
LUH 5868 2-22§ aphA1 K, G, N, T, A 2 FR (1997) 3
RUH 3240 4-2 aacC1, aacC2 2.5 G, N 2 UK (1989) 1, 2
NIPH 1469 4-2 aphA6 K, A 2 CZ (2001) 1
NIPH 1362, NIPH 1711 4-2 2 CZ (2000–2001) 1
LUH 6011 4-21§ aphA1, aacA4 2.2 K, N, T 1 GR (1997) 3
NIPH 657, NIPH 720,
NIPH 732, NIPH 1523
6-4 aacC1, aphA1, aphA6 2.5 K, G, A 2 CZ (1996–2001) 1
LUH 5865 26-2§ aacC2 G, N 2 ES (1998) 3
LUH 6024 26-2§ aphA6, aacC2 K, G, N, A 2 ES (1998) 3
LUH 6044, LUH 6029 26-2§ aphA6, aacC2 K, G, N, T, A 2 ES (1998) 3
Clone III (n 6)
LUH 6028, LUH 6037,
LUH 6035
25-1 aphA6, aadB 0.75 K, G, T, A 9 ES (1997–1998) 3
LUH 6009, LUH 5874 25-1 aphA6, aadB 0.75 K, G, T, A 9 FR (1997) 3
LUH 5875 25-1 aphA6, aadB 0.75 K, G, T, A 9 NL (1997) 3
Other strains (n 8)
NIPH 1717 2-6 aphA1 K 6 CZ (2001) 1
NIPH 301 2-7 aphA1 K, G, N 6 CZ (1994) 1
NIPH 47 8-1 aphA1, aadB K, G, T 6 CZ (1991) 1
NIPH 1445 21-16 aphA1, aadB K, G, T 9 CZ (2000) 1
NIPH 335 21-16 aadB K, G, T 9 CZ (1994) 1
NIPH 1497 23-19 aphA1 K, G, N, T 6 CZ (2001) 1
NIPH 1683 23-19 aphA1 K, G 6 CZ (2001) 1
NIPH 1734 24-20 aphA6, aadB K, G, N, T, A New CZ (2001) 1
*The strain designations used in the previous studies are in parentheses.
†The aacC1 gene was always found in association with aadA1. Genes integrated in class 1 integrons (as concluded from the results of PCRmapping) are
underlined.
‡1, Nemec et al. (2004); 2, Dijkshoorn et al. (1996); 3, van Dessel et al. (2004).
§Novel ribotypes found for clone II strains. These ribotypes differed only in one or two band positions from those typical for clone II.
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resistance phenotypes (Table 1). Strains with aphA1, aacC1
or aphA6 were found to be resistant to kanamycin, genta-
micin or kanamycin+amikacin, respectively, while aadB was
associated with the resistance to kanamycin, gentamicin and
tobramycin. In some strains, the presence of a resistance gene
was associated only with intermediate or decreased suscept-
ibility to a given antibiotic, e.g. the MICs for tobramycin in
five strains with aacC2 were in the range 4–8 gml 1. High-
level resistance to netilmicin was predominantly associated
with the genes encoding netilmicin-modifying enzymes (i.e.
10 out of 16 strains with MICs >64 gml 1 carried either
aacA4 or aacC2) while the majority of strains negative for
these genes (71%) showed intermediate or decreased sus-
ceptibility to this antibiotic (MICs 4–16 gml 1). Low-level
resistance to netilmicin, as frequently found in Acinetobacter
spp., does not seem to be linked to enzymic modification
(Miller et al., 1995) butmight be associatedwith the AdeABC
efflux pump recently described in A. baumannii (Magnet
et al., 2001). In several strains with high-level aminoglycoside
resistance (e.g. LUH 5868, NIPH 301 or NIPH 1497), none
of the genes possibly involved in this resistance was
found, which is also suggestive of additional resistance
mechanisms.
Eighty-nine strains (84%) had a combination of two to five
different resistance genes, and a total of 12 different
combinations were encountered (Table 1). The most fre-
quent combinations, aadA1 + aacC1 + aphA1 (n 24) and
aadA1 + aacC1 + aphA1 + aphA6 (n 23), were detected in
both clones I and II, while the combination of aadA1 + aac-
C1 + aphA1 + aphA6 + aadB (n 13) was confined to clone
I. Combinations of two or three genes encoding resistance to
the same antibiotic (i.e. gentamicin or kanamycin) were
found in 56 strains (53%). The genes (aphA1, aphA6, aadB
and aacA4) encoding kanamycin resistance can serve as an
example. In contrast to the other genes, aphA1 encodes
resistance to kanamycin but not to other clinically important
aminoglycosides such as gentamicin, amikacin or netilmicin.
Forty-five out of the 97 strains resistant to kanamycin carried
both aphA1 and at least one of the other kanamycin-
resistance genes, 31 strains only contained aphA1 and 21
strains carried kanamycin-resistance genes other than aphA1.
Thirteen out of 30 Czech kanamycin-resistant strains from
2000 to 2001 contained both aphA1 and another kanamycin-
resistance gene while other 13 strains carried aphA1 alone.
This, together with a decrease in kanamycin prescribing in
the early 1990s,may indicate the stability of the aphA1 gene in
the A. baumannii population in the absence of an apparent
selective advantage conferred by this gene.
Structural types of the variable regions of class 1
integrons and their association with
aminoglycoside-resistance genes
All strains were investigated for the presence of the integrase
gene intI1 and variable regions of class 1 integrons. Seventy-
eight strains (74%) gave a positive reaction for the intI1 gene
and using the 59CS and 39CS primers, each of these strains
yielded a single PCR product of between 0.7 and 3.0 kb. In
total, amplicons of six different sizes were detected (Table 3).
Amplicons of the same size gave identical restrictions
patterns with HinfI or RsaI, which is indicative of their
structural homogeneity. Comparison of the restriction
patterns did not suggest a structural similarity between
Table 2. Distribution of aminoglycoside-resistance genes andclass1 integron variable regions among theA. baumannii strains
classified into clonal and geographical groups
Resistance gene/
variable region















aacC1 36 11 16 5 68 (64%)
aadA1 36 11 16 5 68 (64%)
aphA1 34 13 16 7 6 76 (72%)
aphA6 32 4 6 6 6 1 55 (52%)
aadB 16 4 1 6 4 31 (29%)
aacC2 7 7 (7%)
aacA4 2 1 3 (3%)
Variable region (kb)
3.0 23 8 2 1 34 (32%)
2.5 13 3 14 4 34 (32%)
2.2 1 1 (1%)
0.8 2 2 (2%)
0.75 6 6 (6%)
0.7 1 1 (1%)
A. baumannii clones
different amplicons, except for the 2.5 and 3.0 kb amplicons,
the HinfI patterns of which differed only by an additional
400 bp fragment present in the 3.0 kb amplicon.
Possible association of integrons with aminoglycoside-resis-
tance genes was investigated by PCRmapping of all integron-
positive strains with the 59CS primer in conjunction with
primers from aacC1, aacC2, aacA4, aadB or aadA1. The
results revealed the association of the 3.0 and 2.5 kb variable
regions with aacC1 and aadA1, the 2.2 and 0.8 kb regions
with aacA4, and the 0.75 kb region with aadB (Table 3). The
aacC1, aadA1 and aacA4 genes were found exclusively as part
of integrons while aadB was integron-associated only in the
strains of clone III. Taken together with the amplified
external non-coding regions, the known sizes of the aacA4
and aadB cassettes (e.g. accession nos AJ313334 and
AF221902, respectively) were sufficient to account for the
entire regions of the 0.8 and 0.75 kb amplicons, respectively.
The results of PCRmapping indicated that the aacC1 cassette
was located at the 59 end of both the 2.5 and 3.0 kb variable
regions while aadA1was located at the 39 end of both of these
regions. In the case of the 2.2 kb variable region, the aacA4
gene was found at the 59 end of the region.
Gombac et al. (2002) characterized a variable region of 2.5 kb
of class 1 integrons found in Italian strains of A. baumannii.
This region consisted of four cassettes, i.e. aacC1, two open
reading frames of unknown functions (orfX and orfX9) and
aadA1 (accession no. AJ310480). The restriction patterns of
the 2.5 kb amplicons of the present study appeared to be
identical to those of Gombac et al. (2002) (not shown).
Sequencing of the 3.0 kb amplicon obtained from isolate
NIPH 7 revealed an array of cassettes with the order aacC1,
orfX, orfX, orfX9, aadA1, with both orfXs having the same
sequence. Thus the 2.5 and 3.0 kb variable regions differ only
by one orfX cassette. To our knowledge, this array of gene
cassettes has been found only in a Serratia marcescens strain
as part of a class 1 integron associated with a Tn1696-like
transposon (Centrón & Roy, 2002; accession no. AF453999),
where the orfX and orfX9 cassettes were termed orfP and
orfQ, respectively.
Dissemination and stability of the class 1 integron
structures
The structurally related 2.5 and 3.0 kb variable regions were
by far the most prevalent integron structures of the present
study (Table 2). They were found in both clones I and II but
not in the other strains. The 3.0 kb region was detected in 34
strains isolated in four countries between 1982 and 2001
while the 2.5 kb regionwas found in 34 strains obtained from
six countries between 1989 and 2001 (Table 1), indicating the
spread of these structures over a relatively large time period.
In addition, the comparison of the sizes, restriction patterns
and gene cassette contents of the amplicons of 0.75, 0.8 and
2.2 kb with those of other studies (Gallego & Towner, 2001;
Gombac et al., 2002; Ribera et al., 2004) suggested the
geographical dissemination of other class 1 integrons with
structurally related variable regions. It has been proposed
that class I integrons comprise conserved and stable variable
regions, with resistance genes transferred more often as part
of the entire integron structure than as individual cassettes
(Martinez-Freijo et al., 1999). Indeed, the complexity of the
2.5 and 3.0 kb regions, their distinctness from other variable
regions found in A. baumannii and their wide dissemination
are indicative of the relative stability of these structures.
Intraclonal and geographical diversity of
aminoglycoside-resistance genes and integrons
Table 2 shows the distribution of the resistance genes and
integron structures among the strains classified into clonal
and Czech or non-Czech groups. The clone III strains were
homogeneous in all properties, which suggests a recent
expansion from a common ancestor. In contrast, the strains
of clones I and II showed a remarkable diversity of both
resistance genes and integron variable regions. As many as
nine and seven resistance gene combinations (including two
to five different genes) were observed among the strains of
clones I and II, respectively (Table 1). This is consistent with
their intraclonal variability in biotype, serotype and plasmid
profile and provides further evidence that these clones are
relatively old groups that have been undergoing diversifica-
tion (Nemec et al., 2004). Thus intraclonal clusters of isolates
with identical or highly similar genomicmarkers and content
of resistance genes may represent particular strains (or
Table 3. Characteristics of the variable regions of class 1 integrons found in this study
Variable region (kb) HinfI digestion products (bp)* Inserted gene cassettes detected by PCR
mapping
3.0 660, 490, 460, 400, 330, 250, 210, 110, 40 aacC1, aadA1
2.5 660, 490, 460, 330, 250, 210, 110, 40 aacC1, aadA1
2.2 770, 690, 430, 160 aacA4
0.8 500, 160 aacA4
0.75 350, 220, 190 aadB
0.7 470, 260
*Fragment sizes as determined by agarose gel analysis; double fragments (as derived from sequence analysis) are underlined.
subclones) that emerge in a restricted geographical area. For
example, all four Czech strains of ribotype R6-4 had the same
resistance genes (aadA1, aacC1, aphA1, aphA6) while the
aacC2 gene was found in all Spanish isolates of ribotype 26-2
(Table 1).
The strains of clones I and II from theCzechRepublic showed
a limited spectrum of both resistance genes and integron
structures as compared to those from other countries (Table
1). The Czech strains contained only the 2.5 and 3.0 kb
integron structures and no aacA4 or aacC2 genes. In contrast,
the aacA4 and aacC2 genes and class I integrons with regions
other than those of 2.5 and 3.0 kb were found in clones I and
II strains from Western Europe. The variations between
geographically separated populations of clonally related
strains may reflect local differences in composition of pools
of resistance genes and/or differences in antibiotic usage
(Miller et al., 1995). Interestingly, Czech populations of both
clones I and II shared all resistance genes (except for aadB
found in clone I only) and integron variable regions. A
possible explanation is that the two highly prevalent clonal
groups of A. baumannii co-occupying a particular ecological
niche and geographical region may more readily share
genetic pools via horizontal gene transfer.
In conclusion, our study results show a remarkable intraclo-
nal diversity of genes encoding aminoglycoside-modifying
enzymes in the pan-European clones I and II. Identical
resistance genes, gene combinations and class 1 integrons
associated with these genes were found in both clones,
indicating that horizontal gene transfer plays an important
role in the dissemination of aminoglycoside resistance. In
addition, the uniformity of the properties found in clusters of
isolates within these clones suggests that clonal expansion
further facilitates the spread of resistance. To unravel
whether there are properties responsible for the wide
occurrence of clones I and II still remains a challenging task.
It is conceivable that both the ancient acquisition of some
resistance determinants and the high capacity to develop or
acquire resistance have contributed to their success. The
investigation of mechanisms of resistance to other groups of
antibiotics and molecular characterization of mobile struc-
tures carrying resistance genes in taxonomically and epide-
miologically well-defined strains will contribute to better a
understanding of the evolution of multidrug resistance in A.
baumannii.
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Relationship between the AdeABC efflux system gene content,
netilmicin susceptibility and multidrug resistance in a genotypically
diverse collection of Acinetobacter baumannii strains
Alexandr Nemec1,2*, Martina Maixnerová1, Tanny J. K. van der Reijden3,
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Objectives: To assess the occurrence of the genes of the AdeABC efflux system and their association
with antimicrobial resistance in Acinetobacter baumannii.
Methods: A set of 116 strains selected for their diversity both in genotypic properties and geographic
origin was investigated for the presence of the structural (adeA, adeB and adeC) and regulatory (adeR
and adeS) genes of the AdeABC system by PCR, for resistance to 11 antimicrobials by disc diffusion, for
MIC of netilmicin and for the presence of aacC2 and aacA4, encoding netilmicin-modifying enzymes.
Results: Ninety-five strains were positive for adeA, adeB, adeR and adeS, 10 were positive for 1 to 3 of
these genes and 11 were negative for all genes. The adeC gene was found in 49 strains with one or more
of the other genes. Forty-one strains were resistant to a maximum of one agent and 75 strains to two or
more agents. Netilmicin MICs showed an almost bimodal distribution with respective peaks of 0.5–1 and
8 mg/L; aacC2 or aacA4 was found in six strains with netilmicin MIC of 64 mg/L. All 61 strains with
netilmicin MICs 4 mg/L were both adeABRS-positive and resistant to two or more agents, whereas
netilmicin MICs 2 mg/L (n 5 51) were found for all strains resistant to a maximum of one agent and
those negative for one or more of the adeABRS genes.
Conclusions: The AdeABC genes are common in A. baumannii, but may be absent in some, mostly fully
susceptible strains. Decreased susceptibility to netilmicin (MIC 4–32 mg/L) is associated with both the
presence of these genes and multidrug resistance and may be indicative of AdeABC overexpression.
Keywords: European clones, AFLP, PCR detection
Introduction
Acinetobacter baumannii is notorious for its involvement in
nosocomial infections and epidemic spread among severely ill
patients.1 The organism is characterized by its ability to evolve
resistance to multiple antibiotics and there are recent reports on
strains resistant to all clinically relevant drugs.2 Over the last
few decades, many resistance mechanisms have been identified
in A. baumannii, of which b-lactamases, aminoglycoside-
modifying enzymes, tetracycline efflux pumps and alteration in
quinolone target sites are considered to be the most important.2,3
In 2001, a novel resistance mechanism, the efflux pump
system AdeABC, was identified in a multidrug-resistant (MDR)
A. baumannii strain.4 This system was shown to be responsible
for decreased susceptibility to a broad spectrum of antimicro-
bials. Although netilmicin and gentamicin appeared to be the
best substrates for the pump, the activity of AdeABC has also
been associated with other agents including b-lactams, fluoro-
quinolones, tetracyclines4 and recently, with tigecycline.5 Three
sequential, clustered genes adeA, adeB and adeC were found to
encode proteins homologous to membrane fusion, drug transpor-
ter and outer membrane components, respectively, characteristic
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A. baumannii
of the RND efflux pump family.6 It was further revealed that a
susceptible A. baumannii strain containing the AdeABC genes
could produce spontaneous resistant variants with mutations in
the adeS or adeR genes, which encode a two-component system
regulating AdeABC expression, and the reduction in suscepti-
bility associated with the efflux system has been attributed to its
constitutive overexpression.7
Elucidation of the AdeABC complex at the molecular and
functional levels has been based mainly on the study of a single
A. baumannii strain, BM4454.4,7 Relatively little is known about
its distribution and biological significance at the population
level. So far, only two studies have reported its occurrence
among multiple A. baumannii strains. Huys et al.8 found adeB
in 49 out of 51 strains originating almost exclusively from
Europe, whereas in another study, 39 out of 56 strains from
Hong Kong tested adeB positive.9 However, the strains of the
first study belonged mostly (80%) to three groups of genetically
related strains (clones), whereas no epidemiological or microbio-
logical data on strains were shown in the second study.
The aim of the present study was to assess the occurrence of
the structural and regulatory genes of the AdeABC system in
a genetically and geographically heterogeneous collection of
A. baumannii strains and to investigate the association of the
AdeABC efflux genes with resistance to antimicrobial agents. In
addition, the role of reduced susceptibility to netilmicin as a ten-




One hundred and sixteen A. baumannii strains used in the present
study were selected from the Leiden University Medical Center
(LUMC) collection. This collection comprises more than 8000
Acinetobacter isolates of which approximately 2000 have been
investigated for their genotype by AFLP whole genome fingerprint
analysis (AFLPTM).10 Cluster analysis of AFLP fingerprints has
allowed assessment of similarities among strains and revealed that
similarities above 50%, 80% and 90% are indicative of related-
ness at the species, clone and strain level, respectively.11 Thus,
using the dendrogram of all fingerprints (data not shown), unique
strains (n 45) or representatives of clusters of strains with similar
genotypes (n 71) were selected at a cluster cut-off level of 80%
in order to cover the overall diversity of the A. baumannii LUMC
collection. The dendrogram of the 116 strains studied is shown in
Figure 1. At a cut-off level of 83%, seven AFLP clusters of strains
were distinguished; three of them corresponded to European clones
I (n 24), II (n 19) and III (n 10) described previously,11–13
whereas the four others (A–D) may represent new clonal lineages.
The strains were obtained from 16 countries between 1982 and 2004
and were from human (n 107) or animal (n 8) specimens or
from the hospital environment (n 1), except for three reference
strains (ATCC 19606T, NCTC 10303 and NCTC 7844) which had
been isolated before 1963 (Figure 1).
Gene detection
The presence of three structural (adeA, adeB and adeC) and two
regulatory (adeS and adeR) genes of the AdeABC system, and two
genes encoding netilmicin-modifying acetyltransferases AAC(3)-IIa
and AAC(6 )-Ib (aacC2 and aacA4, respectively), was determined
by PCR. The primers were those described for adeB,4 for adeC,
adeS and adeR7 and for aacC2 and aacA4.14 To detect adeA, new
primers (A-am: 5 -GCTGAGCCACCACCGGCTAAAG-3 and
A-av: 5 -ACCTTCAACAACGACTCTGTCACC-3 ) with an
expected amplicon size of 990 bp were used in this study. PCR reac-
tions were performed in a final volume of 20 mL containing 10 mL
of Taq PCR Master Mix (Qiagen, Hilden, Germany), 0.2 mM each
primer and 1.5 mL of a DNA suspension obtained by alkaline
lysis.15 The PCR reactions were performed in a FTGENE2D
thermal cycler (Techne, Duxford, UK) with these parameters: initial
denaturation at 948C for 2 min, 35 cycles of 948C for 30 s, 558C for
30 s and 728C for 2 min and a final elongation at 728C for 2 min.
The presence and sizes of amplicons were assessed by electrophor-
esis in 2% agarose gels stained with ethidium bromide.
Susceptibility testing
Susceptibility was determined by disc diffusion following the CLSI
(formerly NCCLS) guidelines16 using Mueller–Hinton agar (Oxoid,
Basingstoke, UK) and 11 antimicrobial agents, which are primarily
effective against susceptible A. baumannii strains. The cut-off
values for resistance were adjusted according to the known distri-
bution of inhibition zone diameters among A. baumannii strains.11
These values were identical to those recommended by the CLSI
guidelines16 for intermediate susceptibility except for tetracycline
and piperacillin, for which the CLSI values for resistance were
used.16 The agents (content in micrograms/disc; resistance break-
point in millimetres) included gentamicin (10; 14), netilmicin (30;
14), tobramycin (10; 14), amikacin (30; 16), ampicillin
sulbactam (10 10; 14), piperacillin (100; 17), ceftazidime
(30; 17), imipenem (10; 15), ofloxacin (5; 15),
sulfamethoxazole trimethoprim (23.75 1.25; 15) and tetra-
cycline (30; 14) (Oxoid). MIC of netilmicin (MAST Group,
Bootle, UK) was determined by the agar dilution method, according
to the CLSI guidelines.16 The netilmicin susceptibility and resist-
ance breakpoints used were 8 and 32 mg/L, respectively.16 All
susceptibility tests were carried out in duplicate and were repeated
twice if discordant results had been obtained.
Results
Detection of the genes associated with the AdeABC
efflux system
PCR results for all five AdeABC-associated genes are shown in
Figure 1 and Table 1. Among 116 strains, 47 (40.5%) were PCR
positive for all genes, 48 (41.4%) were positive for all genes
except for adeC, 1 (0.9%) was positive for all genes except for
adeS, 9 (7.8%) were positive for 1 to 3 genes and 11 (9.5%)
were negative for all 5 genes. Strains belonging to the same
AFLP cluster yielded the same combination of PCR reactions
except for one clone II strain with negative reaction for adeS
and for the strains of AFLP cluster B, which had variable reac-
tions for adeB and/or adeS (Table 1). The strains positive for all
five genes belonged to clone I (n 24), clone II (n 18) or
had unique AFLP genotypes (n 5), whereas strains positive
for all genes but adeC were associated with 25 unique genotypes
and 4 AFLP clusters.
Figure 1. Dendrogram of cluster analysis of AFLP fingerprints of 116 A. baumannii strains included in this study. The origin of strains and the results of
PCR detection of the AdeABC system-associated genes and of susceptibility testing are indicated. AFLP analysis was performed as described previously;10
clusters delineated at a cut-off level of 83% are indicated by boxes. The strains were from humans if not stated otherwise. The presence of the
netilmicin-modifying genes is indicated in parentheses. A, adeA; B, adeB; C, adeC; R, adeR; S, adeS; —, no gene detected.
A. baumannii
Resistance to antimicrobial agents
The percentages of strains resistant to an antimicrobial agent
according to disc diffusion were as follows: gentamicin (56%),
netilmicin (18%), tobramycin (25%), amikacin (28%),
ampicillin sulbactam (24%), piperacillin (56%), ceftazidime
(32%), imipenem (6%), ofloxacin (42%), sulfamethoxazole
trimethoprim (65%) and tetracycline (62%). Table 2 shows the
distribution of the number of agents to which individual strains
were resistant and demonstrates that the vast majority of the
strains were either susceptible to all antimicrobial agents (29%)
or resistant to three or more agents (59%), although only 12% of
the strains were resistant to one or two agents.
Susceptibility to netilmicin
The distribution of netilmicin MICs among the 116 strains is
shown in Figure 2. The MIC values ranged between 0.25 and
128 mg/L with MIC50 and MIC90 being 8 and 16 mg/L,
respectively, and showed an almost bimodal distribution with
the respective peaks being 0.5–1 and 8 mg/L. The genes aacC2
Table 1. PCR detection of the structural and regulatory genes of the AdeABC efflux system in 116 A. baumannii strains classified
according to their AFLP genotype
AFLP genotypea No. of strains adeS adeR adeA adeB adeC No. of resistances per strainb
Clone I 24 6.9 (2–9)
Clone II 18 6.4 (3–11)
1 2 1
Clone III 10 2 6.9 (0–8)
Cluster A 6 2 6.7 (4–10)
Cluster B 2 2 2 2 2 7 (6–8)
1 2 2 2 1
2 2 2 2 2 2 3.5 (0–7)
Cluster C 4 2 2.3 (0–4)
Cluster D 3 2 0.7 (0–2)
Unique 5 3.2 (0–7)
25 2 1.2 (0–9)
2 2 2 1 (0–2)
2 2 2 2 2 1
2 2 2 0
9 2 2 2 2 2 0.2 (0–1)
aAFLP clusters or clones were delineated as shown in Figure 1.
bEleven antibiotics tested. Values are means, with range in parentheses.
Table 2. Distribution of the strains according to the degree of multiresistance and netilmicin MIC
No. of antibiotics to which a
strain was resistant
No. of strains with netilmicin MIC (mg/L)
Total0.25 0.5 1 2 4 8 16 32 64 128
0 1 14 18 1 34
1 1 2 3 1 7
2 1 3 1 1 1 7
3 1 2 1 1 5
4 1 4 (1)a 6
5 1 3 1 (1) 6
6 2 1 3 1 3 10
7 1 1 6 6 3 1 18
8 1 1 2 6 2 (1) 1 (1) 15
9 1 1 (1) 2 5
10 1 1 2
11 (1) 1
aStrains PCR positive for the genes encoding netilmicin-modifying enzymes (aacC2 or aacA) are indicated in parentheses.
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and aacA4, which encode the netilmicin-modifying enzymes
most commonly found in A. baumannii, were found in five
strains and one strain (Figure 1), respectively, all of which had
netilmicin MIC 64 mg/L.
Relationship between the AdeABC system gene content,
netilmicin susceptibility and multidrug resistance
Figure 2 and Table 2 show the relationships between the content
of the efflux genes, MICs to netilmicin and multidrug resistance.
As adeC was shown not to be essential for the efflux function,7
this gene was not included in the following comparisons. Thus,
the strains could be classified into three groups: (i) positive for
all four genes (n 95); (ii) negative for all genes (n 11) and
(iii) positive for one to three genes (n 10) (Figure 2). Except
for four, all strains (n 75) resistant to two or more agents
were positive for all essential genes, whereas among 41 strains
resistant to less than two agents, as many as 17 (41%) strains
yielded negative results for one or more genes (Figure 1).
Figure 2 shows that all strains with netilmicin MICs 4 mg/L
were positive for all four genes, whereas all strains negative for
one or more of these genes had netilmicin MICs 2 mg/L. As
indicated in Table 2, all strains (n 59) with netilmicin
MICs 4 mg/L were resistant to two or more agents, whereas
strains (n 51) with netilmicin MICs 2 mg/L included all
fully susceptible strains.
Discussion
The results of the present study suggest that the AdeABC system
occurs in the vast majority of the A. baumannii population. At
least one of the five genes associated with AdeABC was found
in 91% of all strains. Even if only one representative per AFLP
cluster is considered, as many as 82% of strains were positive
for at least one gene (Figure 1). Most of the 116 strains (82%)
yielded positive PCR results for all efflux genes, except for
adeC, which was found in only 35% of them. The absence of
adeC, which is thought to encode an outer membrane porin,
may be explained by the fact that this porin is not essential for
the efflux function.7 However, negative PCR results obtained
with the specific primers inferred from one sequence have to be
interpreted with caution, as they may result from the polymorph-
ism of DNA regions targeted by primers. Similarly, 10 strains
yielded different combinations of positive and negative results
for adeA, adeB, adeS or adeR (Table 1) and further studies are
required to determine whether the negative results truly indicate
the absence of parts of the efflux system gene cluster considered
essential for the system to function.
To assess the involvement of the AdeABC system in anti-
microbial susceptibility, a simple phenotypic marker of the
efflux up-regulation is needed. Ideally, such a marker should
clearly differentiate between the strictly regulated and
up-regulated efflux forms and should not be affected by other
resistance mechanisms. Even though such a marker is unlikely
to be found among clinically used antimicrobials, the published
data show that decreased susceptibility to netilmicin might serve
as an indication of the up-regulated AdeABC. First, among
different antimicrobial agents, netilmicin and gentamicin
showed the highest differences between the MICs for the MDR
strain BM4454 and its derivative with the disrupted adeB gene.4
Secondly, although clinically relevant aminoglycoside resistance
in A. baumannii has been attributed mainly to enzymatic modifi-
cation of antibiotics,17,18 modification of netilmicin—in contrast
to gentamicin—may be infrequent, especially in countries where
the prescription of netilmicin is low.15 For the identification of
modifying enzymes which can decrease susceptibility to netilmi-
cin, the detection of genes known to encode these enzymes in
A. baumannii can be used.15
In the present study, the netilmicin MIC values showed an
almost bimodal distribution (Figure 2) with the respective peaks
near to the published values for strain BM4454 with up-regulated
AdeABC efflux system (16 mg/L) and its derivative with inacti-
vated adeB (0.5 mg/L).4 Another study7 showed that the chal-
lenge of a susceptible strain (gentamicin MIC, 1 mg/L) with
gentamicin resulted in the selection of mutants with an
up-regulated AdeABC system (gentamicin MIC, 12 mg/L). These
results are also consistent with our data, assuming that
the up-regulation of the AdeABC system leads to similar
increased MIC values of both gentamicin and netilmicin.4 Such
congruency between our data and the quoted data may suggest
that the A. baumannii population forms two major groups accord-
ing to efflux activity. It can be hypothesized that MICs of 0.5–
1 mg/L may reflect the inactivity of the system because of its
stringent regulation, alteration or absence, whereas values 8–
16 mg/L could result from the constitutive expression of the
system. This hypothesis is indirectly supported by our other data.
First, all strains with netilmicin MICs 4 mg/L harboured all
four genes essential for the efflux activity,4,7 whereas all strains
negative for at least one of these genes had MICs 2 mg/L.
Secondly, the genes encoding netilmicin-modifying enzymes
were not detected in any of the strains with netilmicin
MICs 32 mg/L. Finally, comparison of inhibition zone diam-
eters produced by different aminoglycosides in individual strains
did not indicate the involvement of permeability resistance
Figure 2. Distribution of netilmicin MICs among the 116 A. baumannii
strains classified according to the presence of the genes associated with the
AdeABC system. Black bars, positive for adeA, adeB, adeR and adeS, and
variable reactions for adeC; white bars, negative reactions for all five genes;
shaded bars, the remaining combinations of positive and negative reactions
for all genes (Table 1). The vertical arrows indicate the published data for
strain BM4454 with the up-regulated system (16 mg/L) and its derivative
with inactivated adeB (0.5 mg/L).4 Numbers of strains with the genes
encoding netilmicin-modifying enzymes are indicated in parentheses.
Interpretation according to the CLSI breakpoints16 is depicted above the
columns. S, susceptible; I, intermediate; R, resistant.
A. baumannii
(data not shown), which is indicated by a proportional decrease in
susceptibility to all aminoglycosides.19 Thus, all strains with
netilmicin MICs of 4–32 mg/L were associated with all essential
efflux genes, although in none of them were non-efflux mechan-
isms detected. In 6 of 12 strains with MICs 64 mg/L, the genes
encoding netilmicin-modifying enzymes were found, which
could explain the high level of netilmicin resistance, whereas the
absence of these genes in the other 6 strains may indicate the
involvement of other factors.
It is noteworthy that studies conducted by the Schering-
Plough Research Institute in the 1980s indicated a high preva-
lence of the aminoglycoside resistance phenotype similar to that
of BM44544 among worldwide Acinetobacter spp. strains.18 This
phenotype was characterized by low-level resistance to netilmicin
and gentamicin, resistance to two non-clinical derivatives of
netilmicin (2 -N-ethylnetilmicin and 6 -N-ethylnetilmicin) and by
susceptibility to the other aminoglycosides. The hypothetical
mechanism underlying this phenotype was provisionally desig-
nated AAC(3)-?, yet the corresponding acetyltransferase has
never been identified.18 It is conceivable that the AdeABC system
was responsible for AAC(3)-?, suggesting that the up-regulated
form of this system was widespread among A. baumannii strains
more than two decades ago.
In conclusion, the results of the present study are suggestive of
the association between resistance to multiple agents and the
up-regulated AdeABC system in A. baumannii, as indicated by
the observed link between the presence of the genes essential for
the activity of the AdeABC, decreased netilmicin susceptibility
and multidrug resistance. However, although the up-regulated
AdeABC system was shown to transport a wide range of structu-
rally dissimilar compounds, the level of resistance to individual
agents conferred by the system usually does not reach clinical
resistance breakpoints.4,7,20 Values exceeding these breakpoints
are therefore likely to result from the presence of other, more
effective, mechanisms or from a combination of different mech-
anisms.6,21 It has been suggested that increased expression of
chromosomally encoded efflux systems may be the first step in
the bacterium becoming fully resistant.6 Thus, originally suscep-
tible, AdeABC-positive strains may produce mutants with consti-
tutive expression of the AdeABC. It confers low-level protection
that may facilitate the initial survival of the organisms in an
antimicrobial-rich environment such as the hospital and enable
them to acquire subsequently specific, high-level resistance
mechanisms. This could explain why genotypically distinct MDR
strains harbouring different combinations of specific resistance
mechanisms share the up-regulated AdeABC system.
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Objectives: The aim of this study was to analyse the emergence of carbapenem resistance among hos-
pital strains of Acinetobacter in the Czech Republic.
Methods: Acinetobacter isolates were collected prospectively in 2005–06 from 19 diagnostic labora-
tories. They were identified to species level by AFLP, typed using AFLP, pulsed-field gel electrophor-
esis (PFGE) and multilocus sequence typing, and tested for susceptibility to 14 antimicrobials and for
the presence of 20 genes associated with antimicrobial resistance.
Results: A total of 150 Acinetobacter isolates were obtained from 56 intensive care units of 20 hospi-
tals in 15 cities. They were identified as Acinetobacter baumannii (n5 108) or other species. A.
baumannii isolates were allocated to EU clone I (n5 5), EU clone II (n5 66) or other, mostly unique
genotypes. Two-thirds of the clone II isolates had nearly identical AFLP and PFGE fingerprints. As
many as 85% and 88% isolates were susceptible to meropenem and imipenem ( 4 mg/L), respectively.
Carbapenem MICs of 8 mg/L were found in 23 A. baumannii isolates, of which 20 belonged to clone
II. Isolates with blaOXA-58-like (n5 3), blaOXA-24-like (n5 1) or ISAba1 adjacent to blaOXA-51-like (n5 34) had
carbapenem MICs of 2 to >16 mg/L, while those without these elements showed MICs of 0.5–4 mg/L.
Clone II isolates varied in susceptibility to some antibiotics including carbapenems and carried 6–12
resistance genes in 17 combinations.
Conclusions: The emergence of Acinetobacter carbapenem resistance in the Czech Republic is associ-
ated with the spread of A. baumannii strains of EU clone II. The variation in susceptibility in these
strains is likely to result from both the horizontal spread of resistance genes and differential
expression of intrinsic genes.
Keywords: European clonal lineages, AFLP, PCR gene detection, OXA-type carbapenemases
Introduction
Bacteria of the genus Acinetobacter, with Acinetobacter bau-
mannii in particular, are notorious for their involvement in noso-
comial infections and spread among severely ill patients.1 These
organisms are frequently resistant to multiple antimicrobial
agents and there are recent reports on strains resistant to
virtually all clinically relevant drugs. Extensive genotypic
characterization has shown that, within A. baumannii, clusters of
highly similar strains occur, which are assumed to represent dis-
tinct clonal lineages. Of these, the so-called European (EU)
clones I, II and III are widely spread across Europe and include
strains that are usually multidrug-resistant (MDR) and associated
with outbreaks of hospital infections.1–3
Carbapenem resistance in Acinetobacter spp. has emerged as
a significant health problem over the last decade, leaving limited
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Acinetobacter
options for antimicrobial therapy.1 This resistance has been
attributed to the production of carbapenem-hydrolysing
b-lactamases (carbapenemases), although other mechanisms can
also be involved, including those that reduce membrane per-
meability, alter penicillin-binding proteins or expel drugs from
the cell.1 Carbapenemases found in Acinetobacter belong to
molecular class D (OXA enzymes) or class B (metalloenzymes
of IMP- and VIM-type or SIM-1). The OXA carbapenemases of
Acinetobacter are divided into four phylogenetic subgroups:
acquired enzymes OXA-23-like, OXA-24-like and OXA-58-like,
and OXA-51-like enzymes that are intrinsic to A. baumannii.
OXA-51-like enzymes are normally expressed at low levels but
can be overexpressed as a consequence of the insertion of an
ISAba1 sequence upstream of their genes.4,5
Our previous studies showed that resistance of Acinetobacter
isolates to carbapenems was rare in the Czech Republic till the
early 2000s.3,6 However, in 2003 and 2004, A. baumannii iso-
lates resistant to these antibiotics were received by the National
Institute of Public Health (NIPH) in Prague from several hospi-
tals. This observation gave rise to the current study to analyse
the emergence of carbapenem resistance among clinical
Acinetobacter isolates at the country level. We investigated pro-
spectively collected Acinetobacter isolates for their species and
strain diversity, and for susceptibility to carbapenems and the
presence of genes linked to carbapenem resistance. Furthermore,
to obtain a comprehensive view of the situation, the suscepti-
bility and presence of genes conferring resistance to other clini-
cally important agents were determined.
Materials and methods
Collection of Acinetobacter isolates
Acinetobacter strains were collected prospectively from 19 diagnostic
laboratories in the Czech Republic between January 2005 and April
2006. The laboratories were asked to send clinically relevant isolates
of Acinetobacter spp. obtained from patients hospitalized at intensive
care units (ICUs) with no more than one isolate per patient and 10 iso-
lates per ICU. Isolates sent to the NIPH were confirmed for the genus
identity and presumptively identified to species using a set of bio-
chemical tests7 and assessed for susceptibility to 12 antimicrobial
agents using disc diffusion (see below). Isolates from the same ICU
that were indistinguishable from each other according to phenotype
were further typed using ApaI macrorestriction analysis by pulsed-field
gel electrophoresis (PFGE). From each group of isolates with a
common PFGE profile, sharing phenotypic properties and originating
from the same ICU, one isolate was selected for further investigation.
Thus, a final set of 150 Acinetobacter isolates remained from a total of
265 isolates received by the NIPH. The 150 isolates were from 56
ICUs of 20 hospitals in 15 cities and were recovered from sputum (n
69), wounds or pus (n 19), urine (n 17), blood or intravenous cath-
eters (n 15) or from other clinical specimens (n 30).
Genomic fingerprinting and multilocus sequence typing
(MLST)
AFLP genomic fingerprinting performed as described8 was used both
to identify strains to species and to classify them at the subspecies
(clone, strain) level. DNA macrorestriction analysis by PFGE included
digestion of agarose plugs containing genomic DNA with ApaI (New
England Biolabs; 30 U per plug) for 2 h at 258C, followed by
separation of restriction fragments with a CHEF-DRII device
(Bio-Rad) through a 1.2% SeaKem LE agarose gel (Cambrex) in TBE
buffer at 148C for 19 h (pulse times 5–20 s at 6 V/cm). The resulting
PFGE fingerprints were compared visually: patterns that differed in the
position of more than six bands were designated by different capitals,
while those differing in the positions of one to six bands were marked
with the same letter followed by different numerals (Figure 1). MLST
was based on a sequence analysis of the internal portions of seven
housekeeping genes (cpn60, fusA, gltA, pyrG, recA, rplB and rpoB).
Details of the MLST scheme including amplification and sequencing
primers, allele sequences and STs are available at Institut Pasteur’s
MLSTWeb site (www.pasteur.fr/mlst).
Susceptibility testing
Resistance to 12 antimicrobial agents that are primarily effective
against susceptible A. baumannii strains was determined by disc
diffusion following the CLSI guidelines.9 The cut-off values
for resistance were adjusted according to the distribution of inhi-
bition zone diameters among A. baumannii strains.3 The agents
(content in mg/disc; resistance breakpoint in mm) included gentami-
cin (10; 14), netilmicin (30; 14), tobramycin (10; 14), amika-
cin (30; 16), ampicillin sulbactam (10 10; 14), piperacillin
(100; 17), ceftazidime (30; 17), meropenem (10; 15), imipe-
nem (10; 15), ofloxacin (5; 15), sulfamethoxazole trimetho-
prim (23.75 1.25; 15) and doxycycline (30; 15) (Oxoid).
MICs were determined by the agar dilution method according to the
CLSI guidelines using the CLSI susceptibility and resistance break-
points.9 Etest MBL strips (AB Biodisk, Solna, Sweden) as well as a
synergy test using imipenem- and EDTA-containing discs10 were
used to screen for metallo-b-lactamase production.
Gene detection
The presence of the following genes was determined by PCR amplifi-
cation of: the genes encoding the class D carbapenemases
OXA-23-like, OXA-24-like, OXA-51-like and OXA-58-like;11 the
genes encoding the metallo-b-lactamases IMP, VIM and SIM-1;12 the
genes encoding aminoglycoside-modifying phosphotransferases
APH(3 )-Ia (aphA1) and APH(3 )-VIa (aphA6), acetyltransferases
AAC(3)-Ia (aacC1), AAC(3)-IIa (aacC2) and AAC(6 )-Ib (aacA4),
and nucleotidyltransferases ANT(2 )-Ia (aadB) and ANT(3 )-Ia
(aadA1);13 the blaTEM-1-like gene encoding TEM-1-like b-lactamases;
14
the ampC-like gene encoding class C b-lactamases intrinsic to
A. baumannii;15 the tet(A) and tet(B) genes encoding the respective
tetracycline-specific efflux pumps;16 the class 1 integrase gene intI1;13
the adeB and adeR genes encoding the structural and regulatory
proteins of the AdeABC efflux system, respectively,8 and the ISAba1
insertion sequence gene.4 To determine the structure of class 1 integron
variable regions, PCR mapping and restriction analysis of amplicons
obtained by PCR with primers targeting 5 and 3 conserved integron
segments were carried out as previously.13 The location of ISAba1 in
the upstream region of the chromosomal genes encoding OXA-51-like
and AmpC-like b-lactamases was determined according to Turton
et al.4 and Ruiz et al.,17 respectively.
Results
Species diversity and antimicrobial susceptibility
of non-A. baumannii isolates
Using AFLP analysis, the 150 Acinetobacter isolates were
identified as A. baumannii (n 108), genomic sp. 3 (n 30),
Figure 1. Dendrogram of cluster analysis of AFLP fingerprints of 108 A. baumannii isolates in the present study. Clusters of more than two isolates defined
at 80% are marked by vertical lines. Numbers following the city name indicate different hospitals in the city; capitals denote different ICUs in the same
hospital. Indicated are the numbers of antimicrobial agents to which an isolate was resistant using disc diffusion with 12 antimicrobial agents. Positive PCR
results are presented by black boxes. All strains were positive both for ampC-like and blaOXA-51-like, and negative for blaIMP-like, blaVIM-like, blaSIM-1, aacC2
and aacA4. All strains positive for aacC1 were also positive for aadA1. VR 2.5, 3.0 and 3.5 denote three respective variable class 1 integron regions. Positive
PCR results for primer combinations ISAba1-blaOXA-51-like and ISAba1-ampC-like indicate the location of ISAba1 in the promotor regions of blaOXA-51-like
and ampC-like, respectively. The designations of isolates studied by MLST are underlined. RUH 134 and RUH 875 are the reference strains of EU clones II
and I, respectively.2 NT, not tested; blank, negative (except for RUH 134 and RUH 875 for which no data are shown).
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genomic sp. 13 TU (n 8), Acinetobacter calcoaceticus (n 1),
Acinetobacter schindleri (n 1) or Acinetobacter junii (n 1).
One isolate could not be allocated to any of the known
Acinetobacter species. The MICs of imipenem and meropenem for
the non-A. baumannii isolates ranged from 0.125 to 0.5 mg/L.
All non-A. baumannii isolates were fully susceptible to the 12 anti-
microbials tested by disc diffusion, except for four isolates of gen.
sp. 3, which were resistant to gentamicin and tobramycin and/or
ofloxacin, and for one gen. sp. 13 TU isolate that was resistant to
gentamicin and netilmicin. The non-A. baumannii isolates
were negative for all resistance genes except for three amino-
glycoside resistant isolates of gen. sp. 3, which were PCR-positive
for aadB, and for all gen. sp. 13 TU isolates, which were positive
for at least one of the genes associated with the AdeABC efflux
system.
Population structure of A. baumannii isolates
The results of cluster analysis of the AFLP fingerprinting of 108
A. baumannii isolates are shown in Figure 1. Using a cut-off of
80% (which corresponds to the approximate grouping level of
strains of the same clone3,18), the isolates were classified into
one major cluster with 66 isolates, two clusters with 5 isolates
each, 5 pairs and 22 single isolates. The major cluster and one
of the small clusters corresponded to EU clones II and I, respect-
ively, while none of the strains was found to group with strains
of EU clone III (data not shown). Most clone II isolates yielded
identical or highly similar PFGE patterns (Figure 2) and 45
(68%) of the clone II isolates clustered together according to
their AFLP patterns at 90% (Figure 1), indicating that they
were genetically related at the subclonal level.18 MLST was per-
formed for seven clone II isolates that differed from each other
in PFGE/AFLP patterns or/and in resistance phenotype
(Figure 1). Six of them had ST2 (2-2-2-2-2-2-2), which seems to
be the typical ST of EU clone II (L. Diancourt, V. Passet,
A. Nemec, L. Dijkshoorn and S. Brisse, unpublished results),
while NIPH 2578 yielded ST47 (2-13-2-2-2-2-2), a single locus
variant of ST2.
Resistance of A. baumannii isolates to carbapenems
According to MICs, 85 (79%) A. baumannii isolates were sus-
ceptible (MIC 4 mg/L) to both imipenem and meropenem,
while 23 (21%) isolates were either intermediate (8 mg/L) or
resistant ( 16 mg/L) to at least one carbapenem (Figure 1). Out
of the 85 susceptible isolates, 40 had MICs 0.5 mg/L for both
carbapenems, but 45 showed reduced susceptibility (MICs 1.0–
4.0 mg/L) to at least one carbapenem. All 68 isolates with carba-
penem MICs 1 mg/L were also resistant to at least one other
antimicrobial agent and belonged to clone II, clone I or three
unique AFLP genotypes. None of the isolates was PCR-positive
for the genes encoding metallo-b-lactamase IMP-like, VIM-like
or SIM-1. In addition, no metallo-b-lactamase activity was
detected in any of 16 isolates with imipenem MICs 16 mg/L,
using Etest MBL and a double-disc synergy test.
The results of PCR detection of OXA-type carbapenemases
are shown in Table 1. All isolates were positive for
blaOXA-51-like, three were positive for blaOXA-58-like and one for
blaOXA-24-like. Using the ISAba1 forward primer and the
OXA-51-like gene reverse primer, 34 isolates yielded a PCR
amplicon of 1.2 kb, which indicates the location of ISAba1 in
the upstream region of the OXA-51-like gene of these isolates.4
The remaining 74 isolates showed no PCR product, although 37
of them were positive for the ISAba1 sequence (Figure 1). The
isolates with blaOXA-58-like, blaOXA-24-like or/and ISAba1 adjacent
to blaOXA-51-like had carbapenem MICs of 2 to .16 mg/L
(MIC50 8 mg/L and MIC90 16 mg/L), while those without evi-
dence of these genetic structures showed MICs of 0.5–4 mg/L
(MIC50 0.5 mg/L and MIC90 2 mg/L) (Table 1).
Resistance of A. baumannii isolates to non-carbapenem
agents
According to disc diffusion, 33 isolates were fully susceptible to
all 12 antimicrobials, while 75 isolates showed resistance to 3
agents (Figure 1). The MICs of imipenem and meropenem for
the 33 fully susceptible isolates ranged from 0.125 to 0.5 mg/
L, while those of the 75 isolates resistant to 3 agents were
between 0.25 and .16 mg/L. Out of these 75 isolates, 5 and 66
belonged to clones I and II, respectively.
There was a good correlation between the presence of the
genes associated with resistance to non-carbapenem agents and
MIC of these agents. All isolates positive for aphA6 (n 24),
aacC1 (n 60) and aadB (n 1) were resistant to or, in a few
cases, intermediate to amikacin, gentamicin and tobramycin
gentamicin, respectively. All 61 tet(B)-positive isolates showed
doxycycline MICs 32 mg/L, while the tet(B)-negative isolates
had MICs of 8 mg/L. The MICs of ampicillin/sulbactam of
16/8 mg/L were found only in isolates harbouring the
blaTEM-1-like gene (n 53), while all but one isolate with MICs
of 8/4 mg/L were blaTEM-1-like-negative. Using the ISAba1
forward primer and the ampC-like gene reverse primer, 68 iso-
lates yielded a PCR product of 750 bp, which indicates the
presence of ISAba1 in the promoter region of the ampC-like
gene.17 Ceftazidime MICs against these 68 isolates were
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  16
Clone II Clone I
48.5kb
Figure 2. Examples of the ApaI macrorestriction patterns of A. baumannii
isolates. Strains are indicated by the numbers above the lanes: 1, NIPH 2571;
2, NIPH 2895; 3, NIPH 2700; 4, NIPH 2519; 5, NIPH 2981; 6, NIPH 2867;
7, NIPH 2982; 8, NIPH 2990; 9, NIPH 2874; 10, NIPH 2610; 11, NIPH
2578; 12, NIPH 2713; 13, NIPH 2605; 14, NIPH 2666; 15, NIPH 2988; 16,
NIPH 2706. Lane M, molecular size markers (48.5 kb ladder).
32 mg/L, whereas those against 40 isolates without ISAba1 in
the promoter region were 8 mg/L (Figure 1).
Both the adeB and adeS genes that are associated with the
AdeABC efflux system were detected in 96 isolates, while seven
isolates were negative for both genes and five isolates were posi-
tive for only one of the genes. Only the isolates positive for both
genes showed increased netilmicin MICs ( 4 mg/L) (Figure 1),
which may indicate up-regulation of the efflux.8 The class 1 inte-
grase gene was found in 60 isolates (belonging to either clone I or
II) and was unequivocally associated with the aacC1 and aadA1
genes and with PCR products obtained with the primers aimed to
amplify variable integron regions. Three different variable
regions with the respective sizes of 2.5, 3.0 and 3.5 kb were
detected (Figure 1), and restriction analysis and PCR mapping of
these structures revealed that they contained the same genes in
the same order [aacC1-(orfX)1-3-orfX -aadA1], differing only in
the number of orfX copies.13
Heterogeneity of resistance phenotypes and genotypes
within EU clone II isolates
The susceptibility rates of clone II isolates (n 66) according to
the MIC and the CLSI breakpoints9 were as follows (% susceptible
isolates): imipenem (76), meropenem (70), ceftazidime (5), pipera-
cillin (0), ampicillin sulbactam (23), gentamicin (14), tobramy-
cin (80), amikacin (68), netilmicin (12), sulfamethoxazole
trimethoprim (12), doxycycline (6), ciprofloxacin (0) and colistin
(98). As many as 21 different resistance profiles were identified
among these isolates and a similar heterogeneity was revealed at
the gene level. The isolates were positive for the tested genes as
follows (% PCR-positive isolates): blaTEM-1-like (80), tet(B) (92),
tet(A) (5), aacC1 (83), aphA1 (80), aphA6 (30), blaOXA-58-like (3),
intI1 (83) and ISAba1 (95). The integron variable regions of 2.5, 3
and 3.5 kb were found in 8, 46 and 1 isolate, respectively.
Individual strains carried from 6 to 12 resistance-associated genes
in 17 different combinations. Some isolates with the same PFGE
patterns and obtained from the same ICU (e.g. NIPH 2893 and
NIPH 2873) differed in the combination of resistance genes,
whereas other isolates indistinguishable from each other by geno-
type and phenotype originated from different cities (e.g. NIPH
2601 and NIPH 2991) (Figure 1).
Discussion
Of the 150 Acinetobacter isolates in the present study, 146
(97%) were identified as A. baumannii (72%) or other genomic
species of the Acinetobacter calcoaceticus–A. baumannii
complex (25%). Nearly all strains resistant to multiple anti-
microbial agents belonged to A. baumannii, and the vast
majority of these MDR isolates were allocated to EU clone I or
II. These results are consistent with those of our retrospective
study on the A. calcoaceticus–A. baumannii complex isolates
collected in Czech hospitals in 1991–97.3,6 However, whereas in
the present study, 5 and 66 isolates were allocated to clones I
and II, respectively, 39 and 9 isolates from the 1990s were
classified into the respective clones. Even though the results of
the two studies are not directly comparable as the strain
inclusion criteria differed, the data suggest a shift in the recent
A. baumannii population towards clone II.
In the present study, 90% of the isolates with decreased sus-
ceptibility or resistance to carbapenems ( 1 mg/L) and 83% of
those resistant to one or more non-carbapenem agents belonged
to EU clone II. The wide spread of clone II may have resulted
from its selective advantage in the antibiotic-rich hospital
environment and could further be facilitated by the absence of
effective measures to prevent the transmission of MDR microor-
ganisms, a problem commonly encountered in Czech hospitals.
Other European studies have also recently reported on the spread
of strains of clone II and on the association of carbapenem resist-
ance with these strains.18,19 EU clone II thus seems to be parti-
cularly successful in its spread in European countries and it is
conceivable that the ability of clone II strains to develop carbape-
nem resistance has substantially contributed to this spread.
Neither metallo-b-lactamase activity nor the genes encoding
these enzymes were detected in any of the studied isolates.
Table 1. Relationship between carbapenem MICs and the presence of genes associated with the decreased susceptibility or resistance to
carbapenems in 108 A. baumannii isolates
Genesa
No. of isolates
Total no. of isolates
MIC of imipenem/meropenem (mg/L)
0.25 0.5 1 2 4 8 16 .16
No geneb (non-EU clone II) 35/34 2/4 2/1 0/0 0/0 0/0 0/0 0/0 39
No gene (EU clone II) 3/0 1/4 22/17 4/7 3/5 0/0 0/0 0/0 33
ISAba1-blaOXA-51-like
c 0/0 0/0 0/0 13/8 5/5 10/3 4/9 0/7 32d
ISAba1-blaOXA-51-like blaOXA-58-like 0/0 0/0 0/0 0/0 0/0 2/2 0/0 0/0 2
e
blaOXA-58-like 0/0 0/0 0/0 0/0 0/1 1/0 0/0 0/0 1
f
blaOXA-24-like 0/0 0/0 0/0 0/0 0/0 1/0 0/1 0/0 1
f
aAll isolates were positive for the blaOXA-51-like gene and negative for the genes encoding OXA-23-like, IMP, VIM and SIM-1 carbapenemases.
bNeither blaOXA-24-like, blaOXA-58-like nor ISAba1 located in the blaOXA-51-like promoter region was detected.
cISAba1 located in the promoter region of the blaOXA-51-like gene.
dAll except one were EU clone II isolates.
eEU clone II isolates.
fNon-EU clone II isolates.
Acinetobacter
The genes encoding OXA-23-type carbapenemases were not found
either, and those for OXA-24-type or OXA-58-like enzymes were
identified only in four carbapenem-resistant isolates. These data
indicate that carbapenem resistance in Czech Acinetobacter strains
does not result from the presence of acquired carbapenemases. It
has recently been shown that the insertion of an ISAba1 sequence
upstream of the chromosomal genes encoding OXA-51-type
b-lactamases can increase the expression of these genes, which are
normally expressed at a low level, and result in carbapenem resist-
ance.4,5 In the present study, ISAba1 was located in the promoter
region of the blaOXA-51-like gene in half of the clone II isolates and
most of these isolates had higher carbapenem MICs when com-
pared with those devoid of ISAba1 in the promoter region.
However, similar MICs (2–4 mg/L) were obtained for some iso-
lates regardless of the presence or absence of ISAba1 adjacent to
the blaOXA-51-like gene. Carbapenem resistance thus seems to result
from the overexpression of the blaOXA-51-like gene, but other mech-
anisms are probably also involved.
In conclusion, the present study shows that the emergence of
Acinetobacter resistance to carbapenems in the Czech Republic
was associated with the spread of MDR A. baumannii strains
belonging to EU clone II. Carbapenem resistance of these strains is
likely to result from up-regulation of the chromosomal
OXA-51-like b-lactamase rather than from acquisition of other
OXA- or metallo-b-lactamases, but the precise molecular basis of
this resistance remains to be resolved. Although the high genomic
similarity of most clone II isolates suggests that they represent a
recent lineage within the clone, these isolates show a striking vari-
ation in the phenotype and genotype of resistance to several clini-
cally important antibiotics. This variation is likely to result from a
relatively frequent horizontal acquisition and/or loss of resistance
genes as well as from differential expression of intrinsic genes.
This striking genetic versatility may endow EU clone II with the
ability to develop resistance to nearly all clinically relevant agents.
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Figure 1. General mechanisms of resistance to antimicrobial agents in Gram-negative bacteria.






Table 1. Mechanisms of resistance of A. baumannii to clinically important antibiotics
Mechanism Typical resistance to Desription of the mechanism
responsible component
-lactam hydrolysis
ADC* Cephalosporins† AmpC-type -lactamase intrinsic to A. baumannii
TEM-1, CARB-5, SCO-1 Carboxypenicillins Narrow spectrum class A -lactamases
VEB-1, PER*, TEM-92, CTX-M-2 Cephalosporins Broad spectrum class A -lactamases
OXA-51* Carbapenems† Class D -lactamase intrinsic to A. baumannii
OXA-23*, OXA-24*, OXA-58* Carbapenems Class D -lactamases
IMP*, VIM*, SIM-1 Carbapenems Metalo- -lactamases
Aminoglycoside modification
AAC(3)-Ia Gentamicin Ubiquitous acetyltransferase
AAC(3)-IIa Gentamicin, tobramycin Acetyltransferase
AAC(6')-Ib, AAC(6')-Ih Tobramycin, amikacin Acetyltransferases
APH(3’)-I Kanamycin Ubiquitous phosphotransferase
APH(3’)-VI Amikacin Phosphotransferase typical for Acinetobacter spp.
ANT(2’’)-Ia Gentamicin, tobramycin Ubiquitous nucleotidyltransferase
Target alteration
GyrA, ParC Quinolones Subunits DNA topoisomerases
ArmA Aminoglycosides 16 rRNA methylase
Active efflux
AdeABC Aminoglycosides† Chromosomally encoded nonspecific efflux pump 
Tet(A), Tet(B) Tetracyclines Tetracycline-specific efflux pumps
Changes in outer-membrane proteins
CarO Carbapenems Protein responsible for drug infflux
In addition to the above list, a number of resistance mechanisms and/or genes have been reported to occur in A. baumannii that have known 
or putative role in natural or acquired resistance of this species (Dijkshoorn et al. 2007, Peleg et al. 2008). Mechanisms so far identified in 
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recA, cpn60, gpi, rpoD
A.
baumannii
trpE, adk, efp, mutY, fumC, ppa
to A. baumannii ompA csuE
bla
cpn60, gltA, recA, fusA, pyrG, rplB, rpoB
A. baumannii
Spread of EU clones in space and time
strains or clonal lineages within A. baumannii
the aacC1 aadA1 gene cassettes as well as a resistance island related to 
A. baumannii
Table 2. Published data on the origin of A. baumannii  isolates related to EU clones I-III
Isolates 
related to Reference Country (year) of isolation
Main method of
the clonal assigment Study
EU clone I Dijkshoorn et al. 1996 Belgium (1990), the Netherlands AFLP Comparison of European outbreak strains 
Devaud et al. 1982 Switzerland (1977) AFLP* Genetic analysis of an outbreak strain
Nemec et al. 2004
(= Chapter 2)
van Dessel et al. 2004 Italy, Poland, Spain, South Africa AFLP Population analysis of European 
fluoroquinolone-resistant isolates
Abbott et al. 2005 Ireland ( 2004) AFLP* Analysis of a horse isolate
Fournier et al. 2006 France ( 2002) AFLP*, Turton et al. 2007 Completelly sequenced strain AYE
for identification of EU clones
Nemec et al. 2007
(= Chapter 4)
Australia (> 1990), Bulgaria 
(2001), Hungary (1995)
AFLP Analysis of the AdeABC efflux in a diverse 
set of retrospective isolates
Nemec et al. 2008
(= Chapter 5)
Towner et al. 2008 Bulgaria, Croatia, Estonia, 
Greece, Norway, Poland, 
Turton et al. 2007 Population analysis of European 
carbapanem-resistant isolates
Post & Hall 2009 Austraila (1997) Turton et al. 2007 Genetic analysis of a MDR strain
EU clone II Dijkshoorn et al. 1996 Denmark (1984), the Netherlands 
(1982), UK (1989)
AFLP Comparison of European outbreak strains 
Nemec et al. 2004
(= Chapter 2)
van Dessel et al. 2004 France, Greece, Poland, Portugal, 
South Africa, Spain, Turkey (all 
AFLP Population analysis of European 
fluoroquinolone-resistant isolates
Bartual et al. 2004 Spain (1997, 2000-2002) MLST (Bartual et al. 2004) Evaluation of a MLST scheme
Nemec et al. 2008
(= Chapter 5)
Nemec et al. 2007
(= Chapter 4)
Bulgaria (1997), Hungary (1993) AFLP Analysis of the AdeABC efflux in a diverse 
set of retrospective isolates
Towner et al. 2008 Bulgaria, Czech Republic, 
Germany, Greece, Spain, Poland, 
Slovakia, UK
Turton et al. 2007 Population analysis of European 
carbapanem-resistant isolates
Iacomo et al. 2008 Italy (2005) Turton et al. 2007 Completelly sequenced strain ACICU
Whitman et al. 2008 USA (2006) PCR/ESI-MS (Ecker et al. 
2006 )
Cause of pneumonia in a health care 
worker
EU clone III van Dessel et al. 2004 Spain, the Netherlands, France, AFLP Population analysis of European 
fluoroquinolone-resistant isolates
(Huys et al. 2005b)
Study on EU clone III
for identification of EU clones
Nemec et al. 2007
(= Chapter 4)
The Netherlands (2000) AFLP Analysis of the AdeABC efflux in a diverse 
set of retrospective isolates
* Unpublished. Clonal assignment based on additional AFLP analysis performed in the Leiden University Medical Center.
A. baumannii
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Figure 2. Geographic origin and the population structure of the in-detail studied isolates of A. baumannii
from the Czech Republic. A. Results of 77 retrospective isolates from the period between 1991 and 1997 
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Figure 3. Distribution of 108 A. baumannii clinical isolates from the Czech Republic according to the level of 
multidrug resistance and allocation to EU clones. The isolates were prospectively collected from as many as 
56 ICUs in 20 hospitals in the period of 2005-2006 (for the geographical distribution of hospitals see Figure 
2) (Chapter 5). The antimicrobials used were imipenem, meropenem, ceftazidime, piperacillin, ampicillin-
colistin. The 33 fully susceptible isolates belonged to 25 different AFLP genotypes.
0.125 0.25 0.5 1 2 4 8 16
Multidrug resistant† 0/0 5/2 3/7 24/18 17/15 8/11 14/5 4/17 75
Susceptible‡ 13/19 20/13 0/1 0/0 0/0 0/0 0/0 0/0 33
0.25 0.5 1 2 4 8 16 >16
Multidrug resistant 0 10 22 19 10 12 1 1 75
Susceptible 7 26 0 0 0 0 0 0 33
1 2 4 8 16 32 64 128
Multidrug resistant 8 21 8 6 7 2 4 19 75
Susceptible 23 11 0 0 0 0 0 0 33
* Intermediate and resistance values are highlighted
† Resistant to more than two antibiotics which are primarily effective against A. baumanni (see below).
‡ Susceptible to aminoglycosides, carbapenems, ofloxacin, doxycycline, ceftazidime and piperacillin.
Isolates
No. of isolates
MIC for amikacin (mg/l) Total
Isolates
No. of isolates
MIC for tobramycin (mg/l) Total
MIC for imipenem/meropenem (mg/l)*
Table 3. Distribution of minimal inhibitory concentration for carbapenems and 
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